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Cancer is the seventh leading cause of death in Indonesia, after death from trauma, 
perinatal and diabetes mellitus.1 More specifically, the number of new female cancer cases 
was 156.500 in 2006.2 The most frequent female cancer in Indonesia is breast cancer, 
while the incidence of gynecologic cancer is 19%.2 This number is decreasing, as in 2002 
cervical cancer still showed the highest incidence of female cancer in Indonesia3 and this 
may be the result of the Indonesian government collaboration program aimed to prevent 
the widespread of gynecologic cancer and to improve its treatment.4 
For gynecologic cancer patients diagnosed with advanced stage of disease, chemotherapy, 
with or without radiotherapy, are the treatment of choice. Although this treatment has 
no curative intent, chemotherapy does increase progression-free survival and overall 
survival time.5,6 Platinum agents are the mainstay of treatment of cervical cancer both 
in the palliative, adjuvant and neo adjuvant setting.6-9 However, the use of platinum 
containing chemotherapy is accompanied by serious side effects and this is the main 
reason for dose-reductions and preliminary termination of therapy. Indeed, in a study 
of cisplatin toxicity in 400 patients who received high dose of cisplatin weekly, it was 
found that 26.5% patients did not complete the cycles because of cisplatin toxicity. The 
major toxicitiy of cisplatin was nausea and vomiting, whereas ototoxicity, neurotoxicity, 
hematologic toxicity and nephrotoxicity occurred in 1-10% patients who did not complete 
the full cycles of chemotherapy.7 Nausea and vomiting, ototoxicity, neurotoxicity, 
hematologic toxicity and nephrotoxicity were present in 40%, 81%, 40%, 30% and 40% 
of the patients, respectively.7,8
Cisplatin is a cytotoxic agent known for its emetogenic potential: more than 90% patients 
treated with cisplatin and without antiemetic treatment experience chemotherapy-induced 
nausea and vomiting (CINV).9-11 CINV is one of the most distressing side effects12,13 and 
prevention of CINV is the main goal of antiemetic treatment in patients receiving highly 
or moderately emetogenic cytostatic treatment.14 However, in a study on granisetron 
efficacy in patients treated with highly emetogenic chemotherapy, around 20-50% showed 
the delay of treatment because of CINV.
CINV is categorized into 5 groups: acute, delayed, refractory, breakthrough and 
anticipatory CINV. Acute CINV occurs within 24 hours after chemotherapy and 
delayed CINV occurs 24 or more hours after chemotherapy administration and persists 
until 5 days. Anticipatory chemotherapy can be present before, during and following 
chemotherapy and is related to poor control of emesis in previous chemotherapy cycles. 
Some of the stimulants such as taste, odor, perception and anxiety can trigger anticipatory 
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nausea and vomiting. Patients experiencing breakthrough CINV need rescue antiemetic 
medication despite the use of prophylactic antiemetic treatment. Refractory CINV can 
occur if patients did not have complete control of nausea and vomiting in previous 
cycles and experience CINV in the subsequent cycle.16,18 Poor control of acute CINV 
can increase the presence of delayed CINV and potentially impacts patients’ Quality of 
Life (QoL).16,19,20
In the recent years, the insight in the pathophysiology of CINV has improved 
considerably and it is shown that neurotransmitters play an important role in the 
pathogenesis of CINV.15 Dopamine, serotonin and substance P are thought to be the 
main neurotransmitters involved in CINV. Serotonin, substance P and their receptors 
are located in the gastrointestinal tract as well as in the central nervous system. As a 
response to chemotherapeutic agents (or their metabolites), these neurotransmitters 
are released in the gastrointestinal tract or in the medulla oblongata. The stimulation 
by neurotransmitter subsequently produces impulses that are sent to the vomiting 
centre causing nausea and vomiting.15,16 In addition to serotonin and substance P, 
other neurotransmitters such as cannabioids, histamine, dopamine, acethylcholine and 
γ-Amminobutyric-Acid (GABA) are thought to play a role in the nausea and vomiting 
reflex. It is assumed that in total more than twenty neurotransmitters and receptor 
systems contribute to the vomiting reflex, nevertheless the precise mechanisms have 
not yet been clarified.15 
Consequently, nausea and vomiting can be pharmacologically treated and prevented by 
agents which block the receptors of these neurotransmitters, such as dopamine receptor 
antagonists, 5-hydroxytriptamine 3 (5-HT3) receptor antagonists and neurokinin 1 (NK1) 
receptor antagonists. The introduction of 5-HT3 receptor antagonists more than 20 years 
ago was an important step forward in the prevention and treatment of CINV. The use of 
these drugs in patients treated with highly emetogenic chemotherapeutic drugs results 
in a 60-75% response rate with regard to control of CINV and the combination of these 
agents with a corticosteroid further improves response rates to 75-85%.15,17,18 Currently, the 
use of aprepitant, NK1 antagonist, 5-HT3 receptor antagonists and dexamethasone could 
increase the complete protection of acute emesis by another 10-15% in cancer patients.7,19 
Despite these important improvements in the treatment and prevention of CINV, still 20% 
of the patients can not be treated adequately.
The inter-individual variation in response to antiemetic drugs is related to patient and 
treatment characteristics such us age, gender, history of motion sickness, history of morning 
sickness and history of alcohol drinking.9,19 In addition, some pharmacogenetic studies 





1) gene, OCT1 (Organic Cation Transporter 1) gene, 5-HT3 receptor gene and CYP2D6 
gene in explaining variation in response to antiemetics in oncology.20-25 All of these genes 
encode proteins and enzymes involved in the pharmacokinetics or pharmacodynamics 
of antiemetic drugs.
Drug transporters play an important role in pharmacokinetics especially in drug absorption 
in the gastrointestinal tract and drug disposition f.e. passage of drugs across the blood–
brain barrier.26 The transporter ABCB1 has a role in the pharmacokinetics of ondansetron. 
Indeed, in vitro experiments showed that inhibition of ABCB1 resulted in a decrease of 
transepithelial transport of ondansetron.27 In a clinical study with the the 5-HT3 receptor 
antagonists granisetron, tropisetron and ondansetron in cancer patients treated with 
moderately or highly emetogenic chemotherapy, the C3435T variant in the ABCB1 was 
associated with antiemetic response. The patients with the TT genotype showed a 40% 
higher response rate than the carriers of the C allele.20 It is thought that the polymorphism 
in ABCB1 influences passage and thus the availability of ondansetron across the blood 
brain barrier and gastrointestinal tract. 
The 5-HT3 receptor is a ligand-gated ion channel with 5 subunits (A,B,C,D and E)28 and 
for the pharmacological function of the 5-HT3A and 5-HT3A/B receptors the 5-HT3B 
subunit plays a predominant role.29 Polymorphisms in the genes encoding the 5-HT3A and 
5-HT3B receptors may influence the receptor function.30 In the study in cancer patients, 
variants in the gene encoding the 5-HT3A receptor did not show a relationship with 
response to 5-HT3 receptor antagonists24 but such a relationship was shown for genetic 
variants encoding the 5-HT3B and 5-HT3C receptor21,31 and also a polymorphism in 
the 5-HT3D receptor could contribute to the individualized response of 5-HT3 receptor 
antagonists.22
Drug-metabolizing enzymes have an important role in the pharmacokinetics of drugs 
as well.26 All of the 5-HT3 receptor antagonists are metabolized by the hepatic CYP2D6 
family, though in the different proportions.16 Ultrarapid metabolizing patients with a 
duplication of a CYP2D6 allele showed a decrease of ondansetron efficacy, because the rapid 
inactivation of the drug.32,33 Based on the CYP2D6 phenotypes, Ultrarapid Metabolizers 
(UM) indeed showed more severe nausea and vomiting as compared to patients with the 
Extensive Metabolizers (EM) phenotype.23 
Metoclopramide as a dopamine antagonist is the most common used of antiemetic drug 
after chemotherapy treatment in Indonesia. The passage of metoclopramide across the 
blood–brain barrier is influenced by ABCB1 transporter. This model was shown by the 
knock-out mouse which showed that the presence of P-glycoprotein could decrease the 
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metoclopramide concentrations in the brain.34 In case of its metabolism, metoclopramide is 
primarily metabolized by CYP2D6.35 The previous report in two cancer patients presented 
that metoclopramide could induce extrapyramidal syndrome in patients with inactive 
alleles of CYP2D6.36
In summary, despite the availability of effective antiemetic drugs for the treatment and 
prevention of nausea and vomiting in cancer patients treated with highly emetogenic 
chemotherapeutic drugs, their use is far from optimal. 
Nausea and vomiting still occurs in a considerable number of patients and potentially 
impacts both outcome of chemotherapeutic treatment and the patients’ quality of 
life.12,37,38 Indeed, some studies showed impact of poor control of CINV on QoL in cancer 
patients12,37,38 but these effects have never been studied in Indonesian cancer patients. 
One reason for this is the lack of a valid and reliable QoL instrument to assess the QoL of 
Indonesian cancer patients.
In addition, some studies have suggested predictability of response to antiemetic 
treatment in cancer patients20,21,23,25,31,38,39 which could be an effective way to further 
individualize and improve prevention of CINV. However, these studies were carried 
out in Caucasian cancer patients and similar studies in Indonesian cancer patients 
have not yet been performed. Pharmacogenetic findings can not always be simply 
translated among ethnicities due to differences in allele frequencies, haplotypes and gene 
functionality. 
AIMS AND SCOPE
The general aim of this thesis is to optimize the prevention and treatment of CINV by 
exploration of pharmacogenetic biomarkers and to determine the impact of CINV of QoL 
in Indonesian cancer patients. 
Chapter 2 describes the fundamentals and clinical pharmacology including the pharmaco-
genetics of antiemetic drugs applied in oncology. It will clarify the mechanisms of action 
of antiemetic drugs in preventing acute and delayed CINV. In addition, pharmacogenetic 
studies on 5-HT3 receptor antagonists related to the ABCB1 gene, 5-HT3 receptors gene 
and CYP2D6 will be presented as well. 
In the next chapter, the results of a clinical pharmacogenetic study investigating the 
association of variants in the genes encoding ABCB1, the 5-HT3B receptor and CYP2D6 
with CINV in patients with cancer in Indonesia are presented (Chapter 3). In Chapter 4 





between Indonesians and Caucasians as too explore a source for ethnic differences in 
response to 5-HT3 receptor antagonists.
Chapter 5 of this thesis provides the results of a study on the translation and validation of 
the EORTC QLQ-C30 in the Indonesian language. The aim of this chapter is to provide 
a valid instrument which can be used to measure patients’ quality of life. We applied the 
Indonesian version of the EORTC QLQ-C30 in Indonesian gynecologic cancer patients 
as to assess the impact of chemotherapy on QoL and compared QoL at baseline and 5 
days after chemotherapy (Chapter 6). The Indonesian version of EORTC QLQ-C30 and 
SF-36 questionnaires are used in this chapter to measure the patients’ daily functions, 
such as: physical, emotional, role, emotional, general QoL, and symptoms related cancer 
or cancer treatment.
A general discussion is presented in Chapter 7, and Summaries in English and Indonesian 
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ABSTRACT
Objective: Nausea and vomiting are the most distressful side effects of cytotoxic drugs in 
cancer patients. Antiemetics are commonly used to reduce these side effects. However, 
the current antiemetic efficacy is about 70%-80% in patients treated with highly-
emetogenic cytotoxic drugs. One of the potential factors explaining this suboptimal 
response is variability in genes encoding enzymes and proteins which play a role in 
metabolism, transport and receptors related to antiemetic drugs. Aim of this review 
was to describe the pharmacology and pharmacogenetic concepts  of antiemetics in 
oncology.
Method: Pharmacogenetic and pharmacology studies of antiemetic in oncology published 
between January 1997 to February 2010 were searched in PubMed. Furthermore, 
related textbooks were also used for exploring the pharmacology of antiemetic drugs. 
The antiemetic drugs which were searched were the 5-hydroxytryptamine 3 receptor 
antagonists (5-HT3RAs), dopamine antagonists, corticosteroids, benzodiazepines, 
cannabinoids, antihistamines and neurokinin-1 antagonists.
Results: The 5-HT3RAs are widely use in highly emetogenic chemotherapy in 
combination with dexamethasone and neurokinin-1 antagonist, especially in acute 
phase. However, the dopamine antagonists and benzodiazepines were found more 
appropriate for use in breakthrough and anticipatory symptoms or in preventing the 
delayed phase of chemotherapy-induced nausea vomiting. The use of cannabinoids 
and antihistamines need further investigation. Only six articles on pharmacogenetic 
of the 5-HT3RAs in highly emetogenic chemotherapy are published. Specifically, these 
studies investigated the association of the efficacy of 5-HT3RAs and variants in multi 
drug resistence 1 (MDR1) gene, 5-HT3A, B and C receptor genes and CYP2D6 gene. 
The pharmacogenetic studies of the other antiemetics were not found in this review.
Conclusion: It is concluded that pharmacogenetic studies with antiemetics are sparse. 
It is too early to implement results of pharmacogenetic association studies of antiemetic 
drugs in clinical practice: confirmation of early findings is required.
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INTRODUCTION 
Chemotherapy Induced Nausea and Vomiting (CINV) are the most distressing side 
effects in cancer patients treated with chemotherapy and can have a negative impact 
on the patients’ quality of life.1 Moreover, CINV can seriously influence patients’ 
adherence to chemotherapy2 and may thus influence progression free survival and 
overall survival. In the past, before using standard antiemetic drug regimens, nausea and 
vomiting resulted in up to 20% of patients in delay or refusal of chemotherapy.3 Highly 
effective antiemetic drugs are available nowadays and their standardized use increases 
patients’ quality of life.4 However, in patients receiving highly-emetogenic cytotoxic 
drug therapy the proportion of patients experiencing effective antiemetic therapy is 
only 70%-80%.5 One of the factors responsible for variable response to antiemetic drugs 
is the inter-individual difference in biotransformation. Moreover, polymorphisms in 
genes encoding drug receptors related to the antiemetic drugs along with other patient 
related risk factors such as gender, age, and drug related factors such as emetogenic 
potential of chemotherapy may explain inter-individual differences in antiemetic drug 
response.6 
OBJECTIVE
The aim of this paper is to review the mechanism of action and pharmacology and the 
potential role of pharmacogenetics of antiemetic drugs in oncology.
METHODS
Studies on the pharmacology and pharmacogenetics of the 5-hydroxytryptamine 3 
receptor antagonists (5-HT3RAs), dopamine antagonists, corticosteroids, benzodiazepines, 
cannabinoids, antihistamines and neurokinin-1 antagonists were searched in PubMed 
January 1997 to February 2010. In addition, pharmacology textbooks were also reviewed 
to summarize the mechanism and pharmacological effects of antiemetics. 
RESULTS
Pharmacogenetic studies of antiemetics in oncology are scarce and the individual studies 
are relatively small: in four studies more than 200 patients, in one study 120 patients and 






of 5-HT3RAs in Multi Drug Resistence1 (MDR1) gene, 5-HT3 A, B and C receptor genes 
and the CYP2D6 gene. The summary of these studies is listed in Table 2.1.
Furthermore, more articles related with mechanism and pharmacologic effects were found 
in this review. The mechanisms of antiemetics are listed in Figure 2.1. The mechanism 
and pharmacology effect of antiemetics will be discussed below.
Pharmacogenetics of antiemetics in oncologyChapter 2
20
Table 2.1 Pharmacogenetic studies of antiemetics
Ums, Ultra-rapid metabolizers; 5-HT3A, 5-Hydroxytriptamine 3A; 5-HT3B, 5-Hydroxytriptamine 3B; 5-HT3C, 
5-Hydroxytriptamine 3C; ABCB1, ATP Binding Casette, subfamily B, member 1; MDR1, Multi-Drug Resistence 1.
Drugs target
(author, year of publication)
Gene Endpoint N Results
Ondansetron or tropisetron
Kaiser et al. (2002)20




270 UMs demonstrate the highest 
incidence and severity of nausea 
and vomiting. Frequency of UMs 
was 1.5%.
Ondansetron or tropisetron







286 5-HT3B receptor gene may 
serve as genetic predictor for 
antiemetic therapy with the 
deletion AAG variant (OR = 32) 
after adjusted with other risk 
factors of emesis.
Tropisetron







242 There were 21 polymorphisms in 
5-HT3A receptor gene, whereas 
the 15 polymorphisms had 
partial linkage each of them. The 
haplotypes in these genes did not 
have significant association with 











216 The complete control rate of 
nausea and vomiting was higher 
in subjects with ABCB1 TT 
genotype as compared with those 
with TC or CC genotype (92.9% v 
56.1% v 47.6%, P = 0.044)
Ondansetron








120 Variant genotype of K163N was 
associated with vomiting (RR = 
2.62)
Dolasetron or tropisetron







70 5-HT3C receptor gene may not 
serve as genetic predictor for 
antiemetic therapy
DISCUSSION
Chemotherapy Induced Nausea and Vomiting (CINV)
Based on the emetogenic potential, cytotoxic drugs are classified into several categories: 
1) highly-emetogenic, which can cause symptoms in > 90% patients without antiemetic 
drug treatment, 2) moderate risk, which can cause symptoms in 30%-90% of patients 
3) low risk with 10%-30% of symptomatic patients and 4) minimally emetogenic with 







Figure 2.1 Activation of emetic pathway by cytotoxic drugs and site of action of ant-emetic drugs. 
Adapted from [10, 26, 58]. 5-HT, 5 Hydroxytriptamin; D2, dopamine; SP, substance P; H, histamine; M, 
muscarinic; CTZ, chemoreceptor trigger zone; VAP, vagal afferent pathway; 5-HT3RA, 5-HT3 receptor 
antagonist. Emesis pathway solid arrow. Sites of action of drugs dotted arrow.
   Gastrointestinal tract 
         Cytotoxic drug agent                                                     Release of serotonin  
                                                                         In the enterochromaffin cell 
                                                           VAP                 5-HT, SP 
CTZ                                                
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                                       Emesis 
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Cannabinoids NK 1 
antagonists 
Benzodiazepines 
Emetogenicity includes both onset and duration of nausea and vomiting.2 In patients 
receiving a combination of cytotoxic drugs, the classification of emetogenicity is based 
on the cytotoxic drug with the greatest emetogenic potential.8 Specifically, for defining 
the emetogenicity of combination regimens of cytotoxic drugs which required a more 
intensive antiemetic prophylaxis and therapy, the following situations may occur: 1) the 
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Table 2.2 Emetogenicity of chemotherapeutic agents (Adapted from [7])











































minimal emetogenic agent does not contribute to the emetogenicity of the combined 
regimen, 2) the low emetogenic agents will increase the emetogenicity of the combined 
regimen by one level greater than the most emetogenic agent in the regimen, 3) the 
moderately and highly emetogenic agents will increase the emetogenicity of each 
drug in the combined regimen by one level,9 e.g. combination of doxorubicin and 
cyclophosphamide are highly emetogenic, although both drugs alone are classified as 
moderate. 
CINV is categorized as acute (occurring within 24 hours of therapy), delayed (persisting for 
6-7 days after therapy) or anticipatory (occurring prior to chemotherapy administration). 
Breakthrough nausea and vomiting refer to uncontrollable symptoms and need rescue 
antiemetics despite the use of prophylactic antiemetics. Some patients also experience 
refractory nausea and vomiting when they did not receive adequate control of nausea and 
vomiting in prior cycles.2 
Cytotoxic drugs can cause emesis through stimulation in the neuron-anatomical centers: 
1) the emetic center, 2) the area postrema or chemoreceptor trigger zone (CTZ), and 3) 
the vagal nerve afferents.10 The CTZ is sensitive to chemical stimuli, and is the main site of 
action of antiemetic drugs.11 However, the blood-brain barrier which is closely located to 
the CTZ is permeable allowing circulating mediators to act directly to the emetic center.11 
However, newer insight from animal studies suggests that an anatomically discrete vomiting 
center is unlikely to exist. Rather, a number of loosely organized neuronal areas within the 
medulla probably interact to coordinate the emetic reflex. The neurons coordinating the 
complex series of events that occur during emesis have been termed the “central pattern 
generator.” Also, free radical formation appear to have an important role in the induction 
of nausea and vomiting.12 The most important neurotransmitters which involve in emetic 
process are dopamine, serotonin and substance P. However, the receptors of 5-HT1A, 2A, 
2C, 3A, 3B, 4, cannabioid 1 (CB1) and α-adrenergic are also known to be involved in emesis 
mechanism.13 Moreover, µ-opioid receptors are also thought to be involved in mediating 
antiemetic effect in humans.14 
The majority of dopamine, serotonin and substance P receptors are found in the dorsal 
vagal complex, the area postrema and in the gastrointestinal tract. After cytotoxic drugs 
have passed through the blood stream to the gastrointestinal tract, they can cause damage 
to the enterochromaffin cells. This damage causes subsequent release of 5-HT3 and 
stimulates the CTZ and vomiting center via 5-HT3 receptors. Ultimately, this causes 
contraction of abdominal muscles, diaphragm, stomach and esophagus activation and an 






5-HT3 receptors are located centrally in the CTZ of the area postrema and peripherally in 
the vagal nerve terminals. Activation of the vomiting center is caused by direct stimulation 
of 5-HT3 receptors in the CTZ by cytotoxic drugs. Equally, stimulation of vagal afferents 
will be transmitted to the vomiting center through nucleus tractus solitarius.15 Five different 
5-HT3 receptors are known in humans, 5-HT3A, B, C, D and E. 5-HTR3A, 5-HTR3B 
and 5-HTR3C are expressed in the CNS as well as in the vagal nerve terminals, whereas 
5-HTR3D is predominantly and 5-HTR3E is exclusively expressed in the gastrointestinal 
tract. The 5-HT3A and 5-HT3B receptor may be involved in the mechanism of CINV.16
Delayed and acute emesis mechanisms are thought to be different. Acute emesis is mainly 
stimulated by serotonin whereas dopamine and histamine are thought to contribute to 
delayed emesis. Some inflammation mediators, such as prostaglandine, histamine and 
substance P are involved in visceral inflammation which results in delayed emesis.10 
Otherwise, the Positron Emesis Tomography (PET), could be also useful to investigate the 
future pathophysiology of nausea and vomiting, especially in delayed emesis, refractory 
emesis and emesis during multiple cycles of chemotherapy.17
Pharmacology of antiemetic drugs
5-Hydroxytryptamine 3 receptor antagonists [5-HT3RAs]
The 5-HT3RAs are the standard antiemetic treatment for acute CINV in patients treated 
with moderately to highly emetogenic chemotherapy. It has been demonstrated that their 
use in combination with a corticosteroid results in complete protection of acute CINV in 
70-80% of patients receiving highly emetogenic chemotherapy.18,19 The 5-HT3RAs bind 
selectively and competitively to 5-HT3 receptors thereby blocking the emetogenic signals 
to the vomiting center.15
Several 5-HT3RAs, such as dolasetron, granisetron, ondansetron, tropisetron and palonosetron 
are available.16 Table 2.3 shows the pharmacological characteristics of these 5-HT3RAs.
Generally, the 5-HT3RAs are well absorbed from the gastrointestinal tract and undergo first-
pass metabolism after oral administration. The prodrug dolasetron is rapidly metabolized by 
carbonyl reductase to its active form, hydrodolasetron which is 70% bound to plasma proteins. 
This active metabolite is further metabolized mainly by cytochrome P450 [CYP] 2D6.15
Granisetron is metabolized by the liver through N-demethylation, aromatic ring oxidation, 
and conjugation mediated by the P450 CYP3A and CYP1A1 isoenzymes which is 
different from the other 5-HT3RAs. Ondansetron is 70-76% bound to plasma protein 
and is extensively metabolized by CYP3A4 in the liver by hydroxylation of the indole ring 
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followed by glucuronide or sulfate conjugation.Tropisetron is metabolized mainly by the 
liver P450 CYP2D6 isoenzyme through oxidative hydroxylation of the indole ring followed 
by conjugation with glucuronic acid or sulfate which are excreted by the kidneys.15,20
Palonosetron is 62% bound to plasma proteins. Palonosetron’s total clearance is lower 
than the other 5-HT3RAs resulting in a relatively long plasma elimination half-life.21 
Palonosetron is metabolized mainly by CYP2D6 (50%) and followed by CYP3A and 
CYP1A2 mediated metabolism.15
Granisetron, ondansetron and palonosetron have slightly different receptor specificity. 
Palonosetron is a highly selective, high affinity competitive antagonist of the 5-HT3A receptor, 
whereas granisetron is highly specific for all subtypes of 5-HT3 receptors but has little or no 
affinity for 5-HT1, 5-HT2 and 5-HT4 receptors. Ondansetron also binds to the 5-HT1B, 
5-HT1C, α1-adrenergic and µ-opioid receptors. The clinical relevance of these findings is not 
clear.15 Despite the fact that ondansetron has different affinity to 5-HT3B,1B,1C, α-adrenergic 
and µ- opioid receptors as compared to granisetron, many studies have shown that this not 
imply differential efficacy between ondansetron and granisetron.13
Dopamine antagonists
The exact mechanism of action of the dopamine antagonists, prochlorperazine and meto-
clopramide as antiemetic drugs is unclear, but prochlorperazine inhibits apomorphine-
induced vomiting by blocking dopamine D2 receptors [DRD2] in the CTZ. Also 
metoclopramide has shown to directly affect the CTZ in the area postrema by blocking 






Table 2.3 Pharmacokinetic characteristics of 5-HT3 receptor antagonists. Adapted from [13, 20, 
49, 59].
Ondansetron Dolasetron Granisetron Tropisetron Palonosetron
Oral bioavailability 60-70% 76% 60% 60% 97%














t1/2 elimination in healthy 
patients (hours)
3.5-5.5 6.9-7.3 4.9-7.6 5.7 24-64.2 
t1/2 elimination in cancer 
patients (hours)
4 7.5 9-11 8 128 
* Minor.
nerves that transmit afferent impulses from the gastrointestinal tract to the vomiting center 
in the lateral reticular formation.22
The phenothiazine derivative prochlorperazine is primarily metabolized in the liver 
via hydroxylation, oxidation, demethylation, sulfoxide formation and conjugation with 
glucuronic acid. The oxidative reactions are catabolized by CYP2D6. Metoclopramide is 
also metabolized by the liver and its metabolites are excreted in the urine and feces.22,23 
CYP2D6 plays a major role in metoclopramide metabolism, thus poor metabolizer of 
CYP2D6 may have slower elimination of metoclopramide.24 Also the buthyrophenone 
haloperidol shows extensive hepatic metabolism with CYP3A4 being the main enzyme 
involved.25,26 
Corticosteroids
Corticosteroids such as dexamethasone are potent antiemetics and are used in combination 
with other agents. Their antiemetic mechanism of action is uncertain but it is assumed 
that it involves inhibition of the prostaglandin synthesis in the hypothalamus.26
Corticosteroids are metabolized in most tissues, but primarily in the liver through 
glucuronidation and sulfoxidation pathways to biologically inactive compounds.22 
Dexamethasone and methylprednisolon are substrates of CYP3A4.13 
Benzodiazepines
The antiemetic mechanism of action of benzodiazepines, for example lorazepam, is related 
to the combination effects of sedation, reduction in anxiety, and possibly depression of 
the vomiting centre.22,26 
Benzodiazepines bind to plasma protein, varying from 70-99%, and undergo extensive 
metabolism by CYP enzymes.27 The CYP2C19 and CYP3A4/5, CYP2C9 and CYP1A2 
contribute to the metabolism of benzodiazepines.
Cannabinoids
Cannabinoids have an antiemetic effect at the enterochromaffin cells in the gastrointestinal 
tract and an anti-cholinergic effect on cholinergic terminals and Auerbach’s plexus and 
possibly mediate the prostaglandin cyclic nucleotide system.26 Two cannabinoid drugs, 
dronabinol and nabilone, have been approved for CINV. Although there are conflicting data, 
cannabinoids can be used for refractory emesis.23,28,29 Nabilone showed superior efficacy 
compared to prochlorperazine and also the combination of the two agents were better than 
was used alone.30 The use of these agents is limited because of their slow elimination from the 
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body and because of adverse effects such as sedation, dysphoria, vertigo, euphoria, dizziness, 
and dry mouth.29 Cannabinoids are prone to pharmacodynamic and/or pharmacokinetic 
interactions with other drugs. The interaction of cannabinoids with chemotherapeutic agents 
that are sensitive to the alteration of CYP3A function should be closely monitored.31
Antihistamines
The pharmacological effect of the antiemetic drug dimenhydrinate is conceived as result 
of its diphenhydramine moiety. Dimenhydrinate and meclizine have CNS depressant, 
anti-cholinergic, antiemetic, antihistamines and local anesthetic effects. Although its 
antiemetic mechanism of action is unclear, dimenhydrinate has been shown to inhibit 
vestibular stimulation, acting first on the otolith system and in larger doses on the 
semicircular canals. Dimenhydrinate inhibits acetylcholine and it is proposed that this is 
the primary mechanism of action. Dimenhydrinate is widely distributed into body tissues, 
and is metabolized by the liver via CYP450, but limited information is available on which 
specific isoenzyme is involved.22 
Neurokinin-1 antagonist
Aprepitant is a neurokinin-1 receptor antagonist and inhibits the action of substance P 
in the emetic pathways both centrally and peripherally. Substance P, neurokinin-A (NK-
A) and neurokinin-B (NK-B) are members of the tachykinin family. These peptides are 
mediated through three receptors: NK-1, NK-2, NK-3. Substance P displays the strongest 
affinity for NK-1, whereas NK-A and NK-B have strong affinity for NK-2 and NK-3.32 
Recently, substance P has shown to have a role in emesis, especially in delayed emesis.33 
Aprepitant is highly bound to plasma proteins (> 95%) and has an elimination half life of 
9-13 hours making it suitable for once daily administration. Aprepitant is both a substrate 
and a moderate inhibitor of CYP3A4. In addition, aprepitant also induces CYP2C9 and 
CYP3A4 and therefore may be prone to drug-drug interactions.32
Casopitant, a new yet unapproved neurokinin-1 receptor antagonist, has an oral clearance 
of 24.4 L/h/kg in female patients and this agent is both a substrate and weak to moderately 
inhibitor of CYP3A4.34
Variable efficacy of antiemetics
According to the guideline of the American Society of Clinical Oncology on prevention of 
CINV, the combination of neurokinin-1 receptor antagonist, 5-HT3RA and dexamethasone 






addition of lorazepam or alprazolam, or substitution the 5-HT3RA with high dose 
intravenous of metoclopramide or adding dopamine antagonist is recommended in patients 
with suboptimal response.7,8
5-Hydroxytryptamine 3 receptor antagonists [5-HT3RAs]
The use of 5-HT3RAs and the combination with dexamethasone results in complete 
acute emesis protection in 70% of patients receiving a first cycle of highly emetogenic 
chemotherapy. However, they are not very effective in the delayed phase of emesis. Indeed, 
even following complete protection in the acute phase, 40% of patients experience delayed 
symptoms of emesis, which interfere with quality of life. In the outpatients setting, the 
symptoms may be underestimated by health care professionals.2 
Tropisetron, ondansetron and granisetron are considered to have similar efficacy which is 
supported by several clinical studies. A Turkish study showed that the complete response 
rate of these drugs in combination with dexamethasone in the control of acute emesis was 
80% for tropisetron 72% for ondansetron and 72% for granisetron (P = 0.877). These three 
drugs also appeared to have similar side-effect profiles.35
Palonosetron was found to be effective in preventing delayed CINV and it was approved 
by FDA as the first antiemetic drug for preventing both acute and delayed CINV.10 It has a 
higher binding affinity and longer elimination half life as compared to the other 5-HT3RAs 
due to its unique structural characteristics based on a fused tricyclic ring system.36,37 The 
use of palonosetron, aprepitant and dexamethasone as a single day regimen of antiemetic 
combination in cancer patients receiving cyclophosphamide and/or doxorubicin resulted 
in complete protection in 51% of patients with 76% of patients in acute phase and 66% 
of patients in delayed phase of emesis.38 The use of this combination in Japanese patients 
showed protection in 75% of patients in the acute phase compared with 73% in the 
granisetron group. During the delayed phase 57% of patients had complete response in 
the palonosetron group compared to 45% of patients in granisetron group.39
Ramosetron and azasetron are the newest agents of 5-HT3RA. In cancer patients receiving 
highly and moderately emetogenic chemotherapy, the combination of intravenous 
ramosetron and dexamethasone showed 77% of complete response in comparison with 
granisetron and dexamethasone which had 82% of complete response.40 
Azasetron, in combination with olanzapine and dexamethasone could improve the complete 
antiemetic response of cancer patients in the delayed phase. In this study the combination 
of azasetron-dexamethasone and olanzapine-azasetron-dexamethasone was compared in 
patients receiving highly and moderately emetogenic chemotherapy.41 
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Dopamine antagonists 
Metoclopramide is still used for breakthrough CINV symptoms and as adjunctive 
medications in building antiemetic regimens for patients with refractory nausea and 
vomiting. Prochlorperazine has similar efficacy as ondansetron plus dexamethasone in 
preventing delayed nausea vomiting on days 2 to 5.42 However, the use of metaclopramide 
in pediatric and elderly patients is not recommended because of the high incidence of 
dystonic reactions.8,43
Corticosteroids
The complete response rates of dexamethasone are about 15-20% higher when it was added 
to 5-HT3RAs. Dexamethasone is effective in prevention of CINV in both the acute phase 
and delayed phase. Corticosteroids are sometimes underutilized because of their potential 
adverse effects. Because the antiemetic use of corticosteroids is short term, tapering the 
dose is rarely needed.29
Benzodiazepines
Benzodiazepines, especially lorazepam are being used for patients with breakthrough 
symptoms and anticipatory symptoms of CINV.8,23 Olanzapine can improve both patients’ 
quality of life and patients’ complete response in delayed nausea vomiting during the treat-
ment of highly or moderate emetogenic cytostatics.41 In a phase II study, the combination 
of olanzapine, dexamethasone and palonosetron was effective in controlling acute nausea 
and vomiting in patients receiving highly and moderately emetogenic cytostatics.44 
Cannabinoids
Nabilone as antiemetic was superior to placebo, domperidone and prochlorperazine in 
preventing CINV, but not superior to metoclopramide or chlorpromazine. Nabilone also 
did not increase the benefit of 5-HTRAs as antiemetic in CINV.45 The use of cannabinoids 
and olanzapine have been suggested as potentially useful interventions, but data from 
phase III clinical trials are still lacking.46 
Antihistamines
Diphenhydramine or hydroxyzine in the prevention of CINV have not shown any 
antiemetic activity. Antihistamines have a role in the treatment of nausea thought to be 







There is evidence to support the use of a three-drug regimen for prevention of acute 
emesis in highly emetic regimens as a minimum standard of care, including a 5-HT3RA, 
a neurokinin-1 antagonist and dexamethasone.10,11 A randomised phase II study of the 
NK-1 antagonist aprepitant in patients receiving cisplatin showed a complete protection 
in the NK-1 antagonist arm of the study of 93% for acute emesis and 83% for delayed 
emesis compared to 67% for acute emesis and 37% of delayed emesis with granisetron 
and dexamethasone. The addition of aprepitant to the 5-HT3RA and dexamethasone 
can improve the acute emesis protection by a further 10-15% and 20-30% in the delayed 
phase of emesis.19
The efficacy of casopitant was shown in study comparing the combination of casopitant-
ondansetron-dexamethasone and ondansetron-dexamethasone. The addition of casopitant 
could increase the complete antiemetic response at 120 hours by 20% in cancer patients 
receiving highly emetogenic chemotherapy.47
Aprepitant is not available in some countries, and the 5-HT3RAs are relatively expensive and 
may therefore not be an option for some patients. Other agents such as prochlorperazine, 
nabilone, dronabinol and olanzapine may be added, however no studies are available on 
the efficacy and safety of these combinations.46
General remark concerning variable clinical efficacy of antiemetic drugs
The effectivity of antiemetic treatment is also influenced by factors such as age of the 
patients, history of alcohol intake, type of cancer, chemotherapy regimen and course of 
chemotherapy. There are data available from gynaecologic cancer patients showing that 
younger patients who received cisplatin regimen experience significant lower rates of 
nausea and vomiting complete responses. However, patients with the first three course of 
chemotherapy had significant higher complete response with regard to nausea than those 
with chemotherapy after the third course.48 The 5-HT3RAs with long duration of action, 
low risk of drug-drug interactions and once daily dosing are preferred.49 Combination of 
palonosetron and dexamethasone shows no significant differences in complete response 
and complete control of emesis in elderly patients (≥ 65 years) as compared to non-elderly 
patients (< 65 years) who received high and moderate emetogenic cytostatic agent (P = 
1.00).50 In cancer patients with multiple-day chemotherapy, the efficacy of the combination 
of palonosetron and dexamethasone is not significantly different compared to ondansetron 
and dexamethasone in prevention of delayed emesis. Nevertheless, patients still need 
rescue antiemetic treatment to a considerable extent.37 Female gender and a history of 
motion sickness is positively related to efficacy to prevent nausea in patients receiving 
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combination of 5-HT3RA and dexamethasone. In addition, patients with a history of low 
chronic alcohol intake experienced more post chemotherapy vomiting.51 
Pharmacogenetic studies of antiemetics
Differential responses of patients to antiemetic drugs can be due to factors such as age, 
gender, and variations in the activity of enzymes, which are involved in the uptake, 
binding, activation or degradation of these drugs. Table 2.1 summarizes the published 
pharmacogenetic studies of antiemetics. The pharmacogenetic studies about DRD2 
antagonists related with their usage as antiemetics are not found. No pharmacogenetic 
studies on corticosteroids used as antiemetic are known.
Pharmacogenetic studies exploring variation in genes encoding drug receptors
Tremblay et al.52 performed a pharmacogenetic study in German Caucasian cancer patients (n 
= 242), who received moderately to highly emetogenic cytostatic drug regimens. Prophylactic 
tropisetron or ondansetron during chemotherapy was given to the patients. In total, 13 
polymorphisms in the 5-HT3B receptor gene were studied and the frequencies of these 
variants ranged from 0.4% to 0.7%. Homozygotes for the -100_-102AAG deletion variant in 
the promoter region of 5-HT3B receptor gene experienced significantly more vomiting and 
nausea. Patients homozygous for the -100_-102AAG deletion variant of the 5-HT3B receptor 
gene showed the highest intensity of vomiting and nausea after chemotherapy, whereas the 
patients having the wild type showed the lowest score [mean value of episodes of vomiting in 
the first observation period of 1 ± 0.58 v 0.23 ± 0.07; P = 0.02]. The intensity of vomiting of 
heterozygous carriers of the deletion variant was in between the intensity of vomiting observed 
in the homozygous mutant and the wild type carriers. The Odds Ratio (OR) for nausea and 
vomiting was 0.5 [95% CI: 0.1-3.2] in the heterozygous carriers of the deletion variant and 
32 in homozygous carriers of the deletion variant [95% CI: 2.5-422] after adjustment for the 
other predictors of nausea and vomiting, such as age, female gender, glucocorticoids usage, 
and the variant of CYP2D6. However, the frequency of the heterozygous genotype for the 
deletion variant is approximately 20% whereas the frequency of the homozygous genotype 
is only 1.3%. Moreover, the data warrant confirmation with larger sample sizes.
Kaiser et al.6 investigated polymorphisms of the 5-HT3A receptor in 242 Caucasian cancer 
patients with various emetogenic treatments. They included 21 polymorphisms with an 
allele frequency of the variant ranging from 0.2% to 31.1% in their study. The number 
of patients suffering from nausea was 35.9% and higher than the number of patients 






was found. Only patients with the heterozygous Met257Ile polymorphism showed a 
non-significantly lower intensity of nausea and vomiting compared to wild type patients. 
However, the frequency of the Met257Ile variant is very low and there was no single 
individual homozygous for the Met allele. The 5819G>A polymorphism showed a non-
significant higher intensity of nausea and vomiting compared to patients homozygous 
for the G allele. The authors suggest to consider a combination of individual risk factors 
such as age, gender, the emetogenicity level of cytotoxic drug and the polymorphism of 
CYP2D6, as a predictor of emesis risk while a single genetic polymorphism in the 5-HT3A 
receptor gene may not serve as a pharmacogenetic predictor of antiemetic treatment with 
5-HT3RAs in cancer patients.6
A study on polymorphisms of the 5-HT3C receptor gene in 70 Caucasian cancer patients 
receiving dolasetron or ondansetron was performed by Ward et al. The study revealed 
seven novel variants in the 5-HT3C gene with allele frequencies ranging from 1.4% to 
42.9%. The common polymorphisms were 6342C>T, 7051G>A and 7142G>C. There were 
no statistically significant associations between either isolated variants or haplotypes and 
antiemetic efficacy. About 18.6% of patients failed to achieve the optimal protection and 
28.6% of patients experienced nausea. This study concluded that genetic variants of the 
5-HT3C receptor genes may not predictive for antiemetic response of the used drugs.53 
Fasching et al.54 studied 120 Caucasian cancer patients receiving a combination of 
ondansetron-dexamethasone before anthracycline chemotherapy. They explored 1 SNP 
in 5-HT3B receptor gene (Y129S) and 2 SNPs in 5-HT3C receptor gene (A405G and 
K163N) with an allele frequency ranging from 29.9% to 62.1%. The Y129S and A405G 
showed no significant association with the complete response of emesis. However the 
K163N variant was found to be significantly associated with a higher percentage of non 
responders. Wild type and heterozygous patients were reported to have a vomiting episode 
rate of 22%, whereas homozygous patients were reported to have a vomiting episode in 
50% of the patients. The homozygous variants of K163N had hazard ratio of 3.35 (95% CI, 
1.00-11.25) in comparison with the heterozygous patients in acute emesis. Therefore, the 
HTR3C gene could serve as a predictive factor for CINV in patients undergoing moderately 
emetogenic chemotherapy. 
Pharmacogenetic studies exploring variation in genes encoding enzymes 
involved in drug metabolism
The highly polymorphic cytochrome P450 mono-oxygenase system in the liver is 
involved in the metabolism of many drugs. About 20 to 25% of all drugs in clinical use 
are metabolized at least in part by CYP2D6.55 CYP2D6 activity may be classified into 
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one of four categories: 1) poor metabolizers (PM), 2) intermediate metabolizers (IM), 
3) extensive metabolizers (EM), 4) ultrarapid metabolizers (UM).52 The majority of the 
Caucasian population is classified into EM, 5-10% are PM, approximately 2% are UM 
whereas less than 2% of Asians were found to be PM and more than 50% were found to 
be EM.15,53 The frequency of dysfunctional CYP2D6 alleles in Asians is 50% and higher 
than in Caucasians (29%). Therefore, many Asians, including Japanese, Chinese and 
Malay, metabolize CYP2D6 mediated drugs more slowly than Caucasians, because of 
predominantly CYP2D6*10, a highly frequent reduced function allele. Kaiser et al studied 
the clinical impact of genetic polymorphisms in the CYP2D6 gene on 5-HT3RAs response 
in cancer patients. Caucasian patients who were UMs had more vomiting within the 
first 4-h (P = 0.001) and within the 5 to 24 h period (P = 0.03) when given ondansetron 
and tropisetron as prophylactic therapy. This result was supported by the observation 
that tropisetron is primarily dependent on the CYP2D6 isoenzyme for metabolism. The 
frequency of UMs in Caucasians is low (1.5%) and the study must be confirmed with larger 
sample sizes to define the contribution of genotyping.20
In a study investigating patients’ response to ondansetron prophylaxis for post-operative 
nausea and vomiting (n = 250), there were significant differences of vomiting incidence 
in PM, IM, EM and UM (8%, 17%. 15% and 45%, P < 0.01) but not in nausea incidence.56 
Variation in genes encoding drug transporters
A study in cancer patients (n = 216) receiving high or moderate emetogenic cytostatic drugs 
which were given prophylactic tropisetron, ondansetron or granisetron was performed 
to explore an association of ABCB1 3435C>T polymorphism with clinical resistance to 
5-HT3RAs. Overall the proportion of patients who were protected from nausea and vomiting 
was about 60% in the acute phase and 50% in the delayed phase of chemotherapy. Patients 
who were homozygous for the ABCB1 3435T allele responded better to antiemetic therapy 
(92.9%) compared with individuals who were heterozygous (56.1%) or homozygous for the 
ABCB1 3435C allele (47.6%) in the acute phase (P = 0.044). This difference reached statistical 
significance in the granisetron-treated group. However, no statistically significant differences 
were found in the patients treated with tropisetron or ondansetron, which is surprising since 
ondansetron is known to be transported by ABCB1 whereas tropisetron is not. It is likely that 
patients with the TT genotype accumulate higher concentrations of 5-HT3RAs in the brain 
and may benefit more from 5-HT3RA treatment. During the delayed phase of chemotherapy, 
there were no differences in the proportion of complete control of emesis across the genotype 
groups (P = 0.53). The findings of this study need to be confirmed in a cohort treated with 







Despite a wide armamentarium of antiemetic drugs a considerable number of cancer 
patients treated with emetogenic chemotherapy experience nausea and vomiting. 
Pharmacogenetics may help to individualize antiemetic treatment however this field is 
relatively unexplored. Interestingly, drug transporters, metabolism and receptor target 
pathways of 5HT3RAs are known to be polymorphic and have shown to be related to 
efficacy of 5-HT3RAs. However, it is too early to implement the results of the various 
studies into clinical practice. Additional large studies also considering non-genetic risk 
factors are warranted.
Impact of findings on practice
•	 Since only limited pharmacogenetic studies of antiemetic in oncology are known, the 
clinician’s decision regarding antiemetic treatment are currently based on patient’s risk 
factors and profile of emetogenicity of chemotherapeutic drugs rather than on genetic 
variants affecting antiemetic drug reponse.
•	 Genetic variant should be only considered in case of suboptimal antiemetic response 
in patients treated with highly emetogenic chemotherapy.
•	 Other investigators may be encouraged to conduct the pharmacogenetic studies on 
antiemetic drug treatment in oncology.
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ABSTRACT
Objective: Suboptimal treatment of chemotherapy-induced nausea and vomiting 
(CINV) and unsatisfactory response to antiemetic drugs cause impairment of cancer 
patient’s daily functioning. This study was aimed to investigate the association of 
selected germline polymorphisms with ondansetron and metoclopramide response in 
Indonesian cancer patients treated with highly emetogenic chemotherapy.
Methods: We enrolled 202 chemotherapy naïve patients treated with cisplatin at a 
dosage ≥ 50 mg/m2 as monotherapy or as combined chemotherapy. Ondansetron 8 
mg and dexamethasone 8 mg intravenously were the standard antiemetic therapy for 
prevention of acute chemotherapy-induced nausea and vomiting. Metoclopramide 10 
mg orally, 3 times per day as fixed prescription was given until 5 days after chemotherapy 
to prevent delayed chemotherapy-induced nausea and vomiting. Primary and secondary 
outcomes were the occurrence of chemotherapy-induced nausea and vomiting in acute 
and delayed phase. The following single nucleotide polymorphisms were determined in 
ABCB1: rs1045642, rs2032582, rs1128503; in 5-HT3B receptor: rs45460698, rs4938058, 
rs7943062 and in CYP2D6: rs16947 (CYP2D6*2), rs3892097 (CYP2D6*4), rs1065852 
(CYP2D6*10) using Taqman assays.
Results: During the acute phase, 21.8% and 30.2% patients experienced Grade 3 and 
4 nausea and vomiting, respectively, whereas 38.6% patients experienced nausea and/
or vomiting in the delayed phase. Carriers of CTG haplotype of the ABCB1 gene 
experienced Grade 3 and 4 CINV more often than other haplotypes in the delayed 
phase (P < 0.05). No associations were found with the 5-HT3B receptor haplotypes 
and CYP2D6-predicted phenotypes.
Conclusions: Our study shows that in Indonesian cancer patients treated with highly 
cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related 
to an increased risk of delayed CINV.
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INTRODUCTION 
Chemotherapy-induced nausea and vomiting (CINV) is the most common side effect of 
cancer patients treated with highly emetogenic chemotherapy1 and has a significant effect 
on the patients’ daily functioning and well-being.2 Poor control of acute CINV, which occurs 
within 24 hours after chemotherapy, may be used as predictor of delayed CINV.3 However, 
patients with delayed CINV, which persists from 24 to 120 hours after chemotherapy, 
experience more severe impact of daily functioning than patient with acute CINV.4 
The introduction of 5-hydroxytriptamine 3 receptor antagonists (5-HT3RAs) significantly 
improved the control of CINV.4 However, the use of 5-HT3RAs in combination with 
dexamethasone as antiemetic treatment in patients treated with highly emetogenic 
chemotherapy provides only 70-80% complete protection in the acute phase2,6 and 60% 
complete protection in delayed emesis.5 
Ondansetron is the first 5-HT3RA and the most widely used in Indonesia community hospitals. 
Standard antiemetic treatment for prevention of acute CINV in Indonesia is ondansetron in 
combination with dexamethasone. For prevention of delayed CINV, metoclopramide is given 
orally from 24 hours until 120 hours after chemotherapy. We realize that the combination 
of a 5-HT3RA, a neurokinin-1 antagonist and a corticosteroid is more effective and is 
therefore frequently given to cancer patients treated with high emetogenic chemotherapy.6,7 
This combination increases the complete protection of acute emesis, with 10-15% increased 
response in comparison with the combination of 5-HT3RA and a corticosteroid,8,9 currently 
the neurokinin-1 antagonist, aprepitant is not available in Indonesia.
Next to the antiemetic treatment regimen, patient characteristics such as age, gender, 
history of motion sickness, history of alcohol drinking are known to influence antiemetic 
drug efficacy. In addition, in recent years it appeared that also genetic variation in genes 
encoding drug transporters, metabolic enzymes and drug targets may influence drug 
efficacy.3 Indeed, variability in ondansetron transport, biotransformation and receptor 
affinity may cause variations in ondansetron’s efficacy.10 More specifically, ondansetron 
is transported into the blood-brain barrier by the drug transporter P-glycoprotein (P-gp) 
and is partially metabolized by, for example, cytochrome P450 2D6 (CYP2D6) and has 
moderate affinity on the 5-HT3 receptors.10-12
In a previous study, it has been reported that the gene ABCB1 encoding P-gp has a role in 
the pharmacology of ondansetron. The ondansetron transepithelial transport decreased 
when an inhibiting agent was added into a MDR1 cell line. In other words, the passive 
diffusion rate of ondansetron was increased by P-gp.13 This mechanism was found in 
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ABCB1 gene, 3435C>T, showed a significant association with the occurrence of acute 
CINV in cancer patients.13 Regarding ondansetron metabolism, it was reported in a 
Caucasian population that the ultrarapid metabolizers (UM) of CYP2D6 experienced the 
most severe nausea and vomiting after chemotherapy treatment.14 It has been shown that 
ondansetron is mainly metabolized by CYP1A2, CYP2D6 and CYP3A4.15 Finally, other 
studies suggested that variation of 5-HT3B, 5-HT3C and 5-HTR3D receptors could be 
the predictors of 5-HT3RAs’ efficacy in cancer patients.16-18
For metoclopramide, gene variations of protein transporter and drug metabolizing 
enzyme are suggested to influence efficacy and adverse drug reaction.19,20 The passage of 
metoclopramide across the blood brain barrier is also influenced by the P-gp transporter,19 
whereas its metabolism is highly dependent on CYP2D6.20,21
In theory, not only the response to antiemetic drugs may be genetically determined 
but also the susceptibility to emetogenic drugs leading to interindividual differences of 
vomiting and nausea at baseline. However, as our knowledge, there are no studies relating 
genetic variants to severity of chemotherapy-induced emesis. The aim of this study was 
to investigate the association of ABCB1, 5-HT3B receptor polymorphisms and CYP2D6-
predicted phenotypes with ondansetron and metoclopramide antiemetic response of 
Indonesian cancer patients treated with highly emetogenic chemotherapy. 
PATIENTS AND METHODS
Study population
The study population involved various cancer patients in the Oncology Department of Dr 
Sardjito Hospital, Yogyakarta, Indonesia, from January 2009 until April 2010, who were 
treated with cisplatin at a dosage ≥ 50 mg/m2 as monotherapy or in combination chemotherapy 
regimens. Ondansetron 8 mg intravenously and dexamethasone 8 mg intravenously were 
standard antiemetic therapy for prevention of acute CINV. Metoclopramide, 10 mg orally, 3 
times per day as fixed presciption, was given to the patients after cytostatic administration 
until 5 days after chemotherapy in order to prevent delayed CINV.
Patients were eligible for this study if they were ≥ 18 years old with a Karnofsky performance 
scale (KPS) of ≥ 50%. We used self-reported ethnicity. However, to make a more accurate 
assessment of ethnicity also the ethnicity of the parents and grandparents were verified. 
Exclusion criteria were: the presence of nausea or vomiting 24 hours before chemotherapy; 
the use of other antiemetics such as benzodiazepines or neuroleptics, radiotherapy within 
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24 hours before start of chemotherapy, the use of opioids within the last 2 weeks, the use 
of inducers of CYP3A4 or inhibitors of CYP2D6, patients with concomitant diseases that 
might cause nausea or vomiting (e.g. ulcerations or obstruction of the upper gastrointestinal 
system, aspartate aminotransferase/alanine aminotransferase > 2,5 x ULN for patients 
without liver metastases > 5 x ULN for patients with liver metastases, renal dysfunction 
defined by creatinine clearance < 60 ml/min, brain metastases, artificial stoma or pregnancy.
This study has been approved by The Ethical Committee of the Medical Faculty of 
Universitas Gadjah Mada, Yogyakarta, Indonesia. All of the patients signed the consent 
form before enrollment. 
Nausea and vomiting assessment
Every patient completed a daily record up to 5 days starting at initiation of cytotoxic drugs 
administration. The daily record contained the number of episodes of vomiting, the 0-100 
scale of Nausea Visual Analog Scale (NVAS) and the antiemetic therapy that was consumed 
over 5 days. Patients were informed that an episode of vomiting that was separated at least 
1 minute from the previous one counted as single episode.22 
Study outcome definitions
The primary outcome was acute nausea and vomiting which was categorized based on the 
National Cancer Institute Common Toxicity Criteria v.3 (NCI CTC v.3).23 We grouped the 
acute nausea and vomiting into Grade 1-2 and Grade 3-4 nausea vomiting. Patients were 
discharged from the hospital on day 1, a few hours after the cytostatic administration. 
Therefore, we could not categorize the secondary outcome based on the NCI CTC v.3. 
The secondary outcome was delayed nausea and vomiting scored dichotomic (yes or no). 
Patients without delayed emesis (no) were defined as patients without vomiting and/or 
had less than a 5 score on the NVAS scale, while patients with delayed emesis ( yes) were 
patients with vomiting and/or scored ≥ 5 scale of NVAS.24,25
SNPs selection and genotyping assays
Three SNPs in the 5-HT3B receptor gene: rs45460698 (deletion AAG in 5’-UTR position), 
rs4938058 (intron), and rs7943062 (3’ near gene); three SNPs in the ABCB1 gene: rs1045642 
(exon 26), rs2032582 (exon 22), rs1128503 (exon 12) and three SNPs of CYP2D6; rs16947 
(CYP2D6*2), rs3892097 (CYP2D6*4), rs1065852 (CYP2D6*10) were selected from the 
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was based on the following criteria: a minor allele frequency of > 0.2, a validated SNP 
according to the NCBI database, and preferably a perfect Linkage Disequilibrium (LD) 
with other SNPs (for 5-HTR3B receptor gene: D´ = 1 and r2 ≥ 0.7) and/or indications for 
relevance based on previous publications.18,26-29
DNA was extracted from saliva samples. DNA was quantified using Nanodrop (Isogen, 
Maarssen, The Netherlands). Genotypes were established using commercially available 
pre-designed Taqman assays and analysed on ABI 7500 realtime PCR System from Applied 
Biosystems (Nieuwerkerk aan den IJssel, The Netherlands) according to manufactures’ 
protocol of allelic discrimination. As a quality control at least 5% of samples were genotyped 
in duplicate and no inconsistencies were found. Overall genotyping success rate of the 
samples was more than 96%. 
Statistical methods
The genotype frequencies were assessed for deviations from Hardy Weinberg equilibrium 
and they did not deviate from Hardy Weinberg equilibrium. The gPlink software was 
used to estimate the haplotype frequency and to set the individual haplotypes from raw 
genotype data. The estimation of haplotype frequencies/phases was ≥ 0.01 and phases 
consideration was ≥ 0.01.30 
The predicted phenotypes of SNPs in CYP2D6 gene were defined as follows: CYP26*2 is 
an active allele, *10 is a decreased activity allele and *4 is a defective allele.14,31,32 Therefore, 
the definition of extensive metabolizers (EMs) include *2/*2, *2/*10, the intermediate 
metabolizers (IMs) include *2/*4, *4/*10, *10/*10, and poor metabolizers (PMs) include *4/*4.
The χ2 test was performed to test the association of patient characteristics and primary and 
secondary outcome. Moreover, the association of 5-HT3B receptor and ABCB1 haplotypes 
and CYP2D6-predicted phenotypes with primary and secondary outcome were analyzed by χ2 
test. These associations are considered to be the result of ondansentron as the antiemetic drug 
in the acute phase and metoclopramide as the antiemetic drug in delayed phase. A P value of 
< 0.05 was considered as significant association. This study is explorative and hypothesis 
generating, and therefore we decided not to correct for multiple testing.
RESULTS
A total of 202 patients were enrolled in this study. Table 3.1 presents the patient charac-
teristics.
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Table 3.1 Characteristics of cancer patients treated with antiemetics (n = 202)
SD, standard deviation; BMI, body mass index; NA, not applicable because patients have not been pregnant yet
Characteristic
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The most frequent diagnosis was cervical cancer (59.9%), mostly diagnosed as Stage 1 or 2 
of cancer (68.8%). The majority of the patients (90.6%) were treated with an intermediate 
dose of cisplatin (50-70 mg/m2) either as monotherapy or in combination therapy, the 
remaining patients (9.4%) were treated with cisplatin at a dosage of 75-100 mg/m2.
The presence of nausea and vomiting during the acute and delayed phase is presented 
in Table 3.2.
In the acute phase, 21.8% patients experienced acute nausea and 30.2% patients 
experienced acute vomiting, whereas 38.6% patients experienced nausea and/or vomiting 
in the delayed phase. Figure 3.1 and Figure 3.2 present the means of vomiting episodes 
and NVAS score over 5 days. The peak of vomiting episodes and NVAS score was seen 
on day 2, with a gradual decline afterwards. 
Table 3.3 depicts the association between patient characteristics and primary and 
secondary outcome measurements. No significant associations of patient characteristics 
and primary or secondary endpoint were found. However, the data suggest that Grade 
3 and 4 acute CINV and delayed CINV are more frequent in younger patients with 
low performance and a history of motion sickness but the associations did not reach 
significance. The statistical analyses were performed in the female subjects to understand 
the association between gene variants, patients’ characteristic and the primary/secondary 
outcome. However, we found no significant association in the analysis results (data not 
shown).
In Table 3.4 the association of gene haplotypes and phenotypes with primary and 
secondary endpoint are presented. A statistical significant association was found between 
the CTG haplotype in the ABCB1 gene and the presence of nausea and vomiting in 
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Table 3.2 The occurrence of acute and delayed chemotherapy induced nausea and vomiting
CINV, chemotherapy induced nausea vomiting.
n %
Acute nausea
   Grade 1 and 2






   Grade 1 and 2






   None





the delayed phase. Carriers of the ABCB1 CTG haplotype experienced more frequent 
Grade 3/4 CINV compared to the other haplotypes (P < 0.05). Multivariate analysis 
demonstrated that age and gender did not alter this result (data not shown). 
In our population, no predicted phenotypes of CYP2D6, the UMs or PMs were found; 
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Figure 3.2 Mean (± SD) of Nausea Visual Analog Scale over 5 days after initiation of chemotherapy.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Our study confirms that prevention of CINV is suboptimal, ondansetron and dexamethasone 
could prevent about 80% of patients from acute nausea and 70% of patients from acute 
vomiting. In the delayed phase, with metoclopramide, 60% of the patients experienced 
no nausea and/or vomiting. These percentages are lower than commonly seen with newer 
antiemetic drugs such as aprepitant or with the use of 5HT3RAs for prevention during the 
delayed phase but these are no standard therapies in Indonesia. 
To date, the reasons of variability in antiemetic drug response are largely unknown. To 
some extent, patient characteristic such as age and gender may contribute to variable drug 
response. Although we did not find significant association between patient characteristic 
and primary or secondary outcome in this study, a non-significant trend analysis supported 
that young patients were more susceptible to experience higher grade of acute and delayed 
nausea and vomiting. A previous study in cancer patients showed that female gender 
and younger age were associated with higher risk of CINV.9 A reason for not replicating 
these findings in our study is that our patients were mostly women, of relatively young 
age and with a narrow distribution of age, resulting in limited power to find associations 
with gender and age. Remarkably, patients-related risk factors such as age play no role in 
individualizing choice of antiemetic-treatment in patients treated with highly emetogenic 
chemotherapy.33 
Variations in genes which are involved in the pharmacology of antiemetic drugs may 
explain interpatient variability in response to these drugs. Indeed, our study shows that 
carriership of the CTG haplotype in the ABCB1 gene increases the risk of delayed CINV 
and may therefore modify the effect of metoclopramide. In contrast, our study shows that 
genetic variants in ABCB1, 5-HT3B receptor and CYP2D6 are not related to ondansetron 
efficacy in acute CINV. 
Interestingly, while the CTG haplotype of ABCB1 is related to delayed CINV it is not 
related to acute CINV. This could be explained by the mechanism of cisplatin-induced 
nausea and vomiting which is probably mostly mediated by the serotonin release in the 
gastrointestinal enterochromaffin cells, and not in the central nervous system.34 Thus 
the haplotype of ABCB1 which could theoretically increase the amount of ondansetron 
that crosses the blood-brain barrier did not show significant impact in the ondansetron 
response. However, in a previous pharmacogenetic study in Caucasian cancer patients it 
was shown that the TT genotype of 3435C>T of ABCB1 experienced less severe of emesis, 
because it was supposed that higher concentrations of ondansetron were available in the 
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The significant association between the carrier of CTG haplotype in ABCB1 gene and delayed 
nausea vomiting indicates that metoclopramide efficacy is modified by the ABCB1 gene 
variation. The proposed mechanism is that passage of metoclopramide across the blood-brain 
barrier is increased in absence of an active P-gp. Indeed, metoclopramide’s site of action as 
an antiemetic is thought to be in the fourth ventricle, which is located behind the blood-
brain barrier. The role of P-gp in metoclopramide transport in the central nervous system 
is consistent with the finding of and increased metoclopramide concentration in the central 
nervous system in patients with an inactive P-gp leading to extra pyramidal symptoms.19 
In the current study, the percentage of patients who experienced acute nausea and vomiting 
seemed to be higher in carriers of the AAGAG haplotype in 5-HT3B receptor gene, although 
it did not reach statistical significance. Patients carrying the deletion AG haplotype in 
5-HT3B receptor experienced a lower grade of nausea and a higher grade of vomiting in 
the acute phase compared to the other haplotypes. 
We performed a haplotype analysis because we could consider information about human 
evolutionary history and genetic variants by finding the LD.35 Previous studies in Caucasian 
cancer patients used the genotype of 3435C>T of ABCB1 gene and the -100_-102 AAG 
deletion variant of 5-HTR3B gene and performed an association analysis rather than a 
haplotype analysis.13,18 Therefore, we cannot compare our study findings with the previous 
studies in Caucasian cancer patients. Teh et al. reported that the allele frequencies in 
3435C>T of ABCB1 gene were different between Asians and Caucasians. 
Among our patients, no predicted phenotypes of CYP2D6 PMs or UMs were identified and 
the frequency of EMs exceeded that of the IMs. Similar results were found in a previous 
study in healthy subjects of Malaysian Chinese origin, presenting that there were no PM 
and the frequency of EM in this population was also around 60%.31 Indeed, in subjects of 
Asian origin the PM phenotype is very rare. The previous study of Kaiser et al. in Caucasian 
cancer patients showed that a different antiemetic response to ondansetron was found in 
both CYP2D6 UMs and PMs. The PMs and UMs showed the lowest and the highest score 
of nausea and vomiting in acute phase, respectively.14 Since the incidence of predicted 
phenotypes of CYP2D6 PMs and UMs in subjects with Indonesian origin is very low, the 
role of CYP2D6 phenotype in explaining variability in ondansetron and metoclopramide 
efficacy in Asians seems to be limited if present at all. 
While there are two reports suggesting that CYP2D6 has a significant role in metoclopramide 
metabolism,20,21 we found no association between CYP2D6-predicted phenotype and 
metoclopramide efficacy. The EMs and IMs as the only predicted phenotypes found in 
our study may be the reasons for these results.
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In conclusion, our study suggests that the carriers of CTG haplotype of ABCB1 gene have 
increased risk of CINV during the delayed phase. However, variants in the genes encoding 
ABCB1, CYP2D6 and 5-HT3B receptor are not associated with antiemetic efficacy of 
ondansetron in Asian cancer patients during the acute phase. Further studies are needed 
to confirm the application of these results in clinical practice.
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ABSTRACT
Background: The 5-hydroxytryptamine 3 (5-HT3) receptor is a ligand-operated ion 
channel with five different receptor subunits (5-HT3A, B, C, D, and E) found in humans. 
Activation of 5-HT3 receptors causes various effects such as drug-induced emesis 
and behavioral effects such as anxiety, depression and cognitive disorders. To explore 
interethnic differences in 5-HT3 receptor antagonists response, we studied haplotype 
frequencies in the gene encoding the 5-HT3B receptor in Asians and Caucasians.
Methods: Three SNPs of 5-HT3B receptor gene, deletion AAG in 5’-UTR position, 
18792A>G in intron position and 46698G>A in 3’ near gene position were selected and 
genotyped in 165 Indonesian cancer patients and 188 Caucasian healthy volunteers. 
Haplotypes were set with gPlink, whereas the difference in haplotype frequencies 
between Indonesians and Caucasians was compared using multivariate analysis.
Results: The haplotype profiles based on the deletion AAG, 18792A>G and 46698G>A 
were AAGAA, AAGAG, AAGGG and deletion AG in both of Indonesians and 
Caucasians. The frequency of the AAGAG haplotype in Indonesians was 54.8% and in 
Caucasians it was 39.9% (P < 0.05). The frequency of AAGGG haplotype in Indonesian 
was 14.3% and in Caucasians was 29.3%. Moreover, there were significant differences 
the frequencies of haplotype pairs between Indonesian and Caucasian (P < 0.001).
Conclusion: Indonesian cancer patients had significantly different AAGAG and 
AAGGG haplotype frequencies of the gene encoding the 5-HT3B receptor compared 
to healthy Caucasians. This finding could be useful for understanding interethnic 
differences in drug response of drugs targeting the 5-HT3B receptor in cancer treatment 
related emesis.
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INTRODUCTION 
The 5-hydroxytryptamine-3 (5-HT3) receptor is a ligand-operated ion channel.1 This 
receptor is found in abundance on parasympathetic terminals in the gastrointestinal 
tract, on the nucleus tractus solitarii and area postrema of central nervous system (CNS).2 
Therefore, this receptors contribute to neuropsychiatric function and the regulation of 
gastrointestinal functions.3
Until now, there are five different receptor subunits of the 5-HT3 receptor in humans: 
5-HT3A, B, C, D, and E. The 5-HT3A, B and C are most expressed in the CNS and in 
the peripheral nervous system, whereas the 5-HT3E receptor is mainly and the 5-HT3D 
predominantly expressed in the gastrointestinal tract, with the activation of 5-HT3 receptors 
resulting in various effects, such as emesis and behavioral effects, such as anxiety, depression 
and cognitive disorders.4 
Several studies in Caucasians have shown an association between polymorphisms in the 
gene encoding the 5-HT3B receptor and antiemetic response to 5-HT3 receptor antagonists. 
5-HT3 receptor antagonists are frequently used in the prevention and treatment of emesis 
and vomiting related to drug treatment.5,6 In addition, some variants of the gene encoding 
this receptor subtypes have been thought to contribute to neurological and psychiatric 
disorders.5 Specifically, the pharmacogenetic studies of genetic variants of the 5-HT3B 
receptor showed that the deletion AAG at position 100 to 102 was significantly associated 
with failure of response to 5-HT3B receptor antagonists in chemotherapy-induced nausea 
and vomiting in Caucasians.6 In Japanese patients with depressive and anxiety disorders, 
this variant was associated with paroxetine-induced emesis, next to major depression 
and etiology of bipolar affective disorders.6,7 Finally, another study explored possible 
associations between genetic polymorphisms in nine exons of gene encoding the 5-HTR3B 
receptor in relation to the occurrence of postoperative nausea and vomiting. This study 
suggests that 5-HT3B receptor variants may have significant impact on the incidence of 
postoperative nausea and vomiting.8   
Today, only limited data are available on haplotypes in the gene encoding the 5-HT3B 
receptor in Asian population. The aim of this study was therefore to establish allele and 
haplotype frequencies of the 3 single nucleotide polymorphisms (SNPs) in the gene 
encoding 5-HTR3B receptor; rs45460698 (deletion AAG in 5’-UTR position), rs4938058 
(18792A>G in intron position), and rs7943062 (46698G>A, in 3’ near gene position) in 
Asians and to compare the frequencies with those of a Caucasian population. 
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DNA from 165 Indonesian cancer patients and from 188 Caucasian healthy volunteers 
was collected for genetic analysis. The Caucasian subjects were men (66%), women (34%) 
with a mean of age 46.4 ± 13.3 (mean ± SD). However these numbers were calculated 
from 96 subjects of 188 Caucasian subjects, because the blood donation foundation 
(Sanquin, The Netherlands) did not provide the characteristics of the remaining donors. 
The Indonesian cancer patients were recruited at the Sardjito hospital Yogyakarta 
between January 2009 and November 2009. Most of the cancer patients were women 
(89.1%) with the diagnoses of cervical cancer (58.8%), ovarian cancer (24.8%), vulva 
cancer (0.6%) and other cancer (15.8%); the remaining patients were men (10.9%) with 
a diagnoses of nasopharyngeal cancer. They were first diagnosed as cancer patients at 
stage I and II (69.1%) and stage III and IV (30.9%). These patients were treated with 
cisplatin, considered as highly emetogenic chemotherapy and received antiemetics 
as well. DNA from these subjects was isolated from saliva samples using OrageneTM 
DNA self-collection kit (DNA Genotek Inc., Ottawa, Ontario, Canada) according to 
manufacture’s prescription. DNA derived from anonymized Caucasian healthy volunteers, 
was isolated from EDTA anti-coagulated blood using the MagnaPure Compact (Roche 
Diagnostics, Almere, The Netherlands). The Institutional Review Board of Gadjah 
Mada University, Yogyakarta, Indonesia approved the study and gave informed consent 
before enrolment in the study. DNA was quantified using Nanodrop (Isogen, Maarssen, 
The Netherlands). 
Genotypes were established using Taqman assays and analysed on  ABI 7500 realtime 
PCR System from Applied Biosystems (Nieuwerkerk aan den IJssel, The Netherlands) 
according to the manufacturer’s protocol.
Polymorphism selection
Three SNPs in the 5-HT3B receptor gene, rs45460698 (deletion AAG in 5’-UTR posi-
tion), rs4938058 (18792A>G in intron position), and rs7943062 (46698G>A, in 3’ near 
gene position) were selected from the National Center for Biotechnology Information 
(NCBI) SNP database. There were 4 criteria for selection of the SNPs: a minor allele 
frequency of > 0.2, a validated SNP according to the NCBI database, and preferably a 
perfect linkage disequilibrium (LD) with other SNPs in 5-HTR3B receptor gene (D-prime 
value = 1 and r2 ≥ 0.7) and/or indications for relevance based on previous publications. 
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The SNP rs45460698 was chosen based on the associations with antiemetic response 
to 5-HT3RAs as shown in previous studies.8,9 The SNP rs45460698 was chosen based 
on the associations with antiemetic response to 5-HT3 receptor antagonists as shown 
in previous studies [8,9]. The SNP rs4938058 is in LD with 6 other SNPs (rs7103572, 
rs11214769, rs12270070, rs2276307, rs4936285, rs12795805) and the rs7943062 is in LD 
with the rs11214763 SNP and they were therefore chosen as tagging SNPs. In contrast 
to the rs45460698 SNP, the rs4938058 and rs7943062 SNPs were not specifically studied 
in relation to 5-HT3 receptor antagonist response but it is expected that any functional 
variant in the gene encoding the 5-HT3 receptor will potentially influence the response 
to the HT3 receptor antagonists and therefore these 2 SNPs were also included in the 
study. 
A challenge in any candidate gene pharmacogenetic study is the selection of polymor-
phisms. We applied several selection criteria under the assumption that these criteria 
increased the informative value of the SNP in relation to clinical and functional effects on 
the gene. However, the HTR3B gene is highly polymorphic meaning that our SNPs only 
represent only a fraction of the possible variation in the population.
5-HT3B receptor gene haplotypes
For the estimation of haplotype frequency and the setting of individual haplotypes from 
raw genotype data we used the gPlink software with default settings. The estimation of 
haplotype frequencies/phases was above or equal to 0.01 and phases consideration was 
above or equal to 0.01 (http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml, accessed 
on 22 August 2010).
Statistical analysis
The genotype frequencies were assessed for deviations from Hardy Weinberg equilibrium. 
The differences in haplotype frequency between Indonesians and Caucasians were 
compared using multivariate analysis. A P value < 0.05 was considered significant.
RESULTS
The estimated genotype distributions of the three 5-HT3B receptor SNPs in Indonesians 
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The haplotypes based on LD pattern of the deletion AAG in 5’-UTR, position 18792A>G 
in intron position and 46698G>A in 3’ near gene position were AAGAA, AAGAG, 
AAGGG and deletion AG in both the Indonesians and Caucasians. Significant differences 
of haplotype frequencies between Indonesians and Caucasians were found for the 
AAGAG and AAGGG haplotypes (P < 0.05). The frequency of AAGAG haplotype was 
significantly higher in Indonesians than in Caucasians (54.7% vs 39.4%). The frequency 
of the AAGGG haplotype in Caucasians was significantly higher than that in Indonesians 
(29.3% vs 14.3%). 
Based on the multivariate analysis, there were significant differences of the haplotype pairs 
frequencies between Indonesians and Caucasians (P = 0.001) (Table 4.2).
Table 4.3 presents the frequencies of haplotype pairs both in Indonesians and Caucasians. 
AAGAG-AAGAG had the highest haplotype pair frequency percentage (23.9%) and 
deletion AG-deletion AG the lowest (2.8%).
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% (n = 349)#
5-HTRB receptor 
18792A>G
% (n = 337) #
5-HTRB receptor 
46698G>A
% (n = 333) #
AAG-AAG del- AAG del-del AA GA GG GG GA AA
Indonesians 69.5 26.8 3.7 74.7 22.2 3.2 74.1 24.7 1.2
Caucasians 76.8 21.6 1.6 53.1 36.9 10.1 68.4 26.9 4.7
# The numbers reflect the number of individuals with successful genotype calls.
Table 4.2 Multivariate analysis of 5HT3B receptor haplotypes and ethnicity
Haplotype P value Odd ratio (Indonesians vs. Caucasians) 95% confidence interval
AAGAG < 0.001 1.50 1.18-1.91
deletion AG 0.212 1.49 0.72-2.09
AAGGG < 0.001 0.58 0.43-0.79
AAGAA 0.181 0.81 0.59-1.13
DISCUSSION
To the best of our knowledge, this is the first study to report the haplotypes frequencies in 
the 5-HT3B gene in Asians. The study shows that the frequencies of AAGAG and AAGGG 
haplotypes in the gene encoding 5-HT3B receptor differ significantly between Indonesians 
and Caucasians. This finding may be helpful to understand interethnic variation of disease 
and drug response related to the 5-HT3B receptor.10 We compared allele frequencies in 
Indonesian cancer patients and Caucasian healthy subjects. To rule out a disease effect, a 
comparison with Caucasian cancer patients may have been preferable. However, since the 
study by Tremblay9 reported comparable genotype frequencies of the insertion/insertion, 
insertion/deletion and deletion/deletion genotypes of the -100_-102deletion AAG variant 
(78.1%, 20.7%, 1.2% respectively) in Caucasian cancer patients as we found in Caucasian 
healthy subjects (76.8%, 21.6%, 1.6% respectively), an effect of disease on allele frequencies 
is not very likely. In most pharmacogenetic studies regarding the 5-HT3B receptor gene, 
the deletion AAG variant was studied for association with drug response phenotypes. In 
an in vitro study about the functional characterization of the -100_-102 deletion AAG, it 
was shown that this variant allele affects the 5-HT3B receptor promoter activity by 25-40%, 
possibly as a result of interference with mRNA.11 This finding has led to the establishment 
of an association between this variant and clinical responses. 
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AAGAG-AAGAG 50 (31.8) 28 (16.6) 78 (23.9)
AAGAG-AAGGG 19 (12.1) 34 (20.1) 53 (16.3)
AAGAG-AAGAA 25 (15.9) 27 (16.0) 52 (16.0)
AAGAG-deletion AG 28 (17.8) 18 (10.7) 46 (14.1)
AAGGG-AAGGG 5 (3.2) 18 (10.7) 23 (7.1)
AAGGG-AAGAA 8 (5.1) 15 (8.9) 23 (7.1)
deletion AG-AAGGG 8 (5.1) 14 (8.3) 22 (6.7)
AAGAA-AAGAA 2 (1.3) 8 (4.7) 10 (3.1)
deletion AG-AAGAA 6 (3.8) 4 (2.4) 10 (3.1)
deletion AG-deletion AG 6 (3.8) 3 (1.8) 9 (2.8)
For example, a study in Caucasians found that patients with the deletion AAG experienced 
more frequent vomiting after chemotherapy than patients with the other 5-HT3B genotypes. 
The study result supported that failure of response to 5-HT3 receptor antagonists, such 
as ondansetron and tropisetron, was related with this deletion of the 5-HT3B receptor 
gene.9 In a second pharmacogenetic study on paroxetine-induced nausea, it was shown 
that patients with the deletion AAG had significantly more frequent nausea than patients 
with the homozygous wild type genotype.6 Yet, in a third study of the influence of 5-HT3B 
receptor variants to the occurrence of post operative vomiting (POV), it was found that 
the 100-102 deletion AAG did not have any significant association with the occurrence of 
POV. However, these authors showed that another deletion variant, the 201-202 deletion of 
CA, significantly influenced the POV incidence.8 Likewise, in our study, the frequency of 
the deletion AAG and the haplotype including the deletion was not significantly different 
between Indonesians and Caucasians. However, there were significant differences between 
the Indonesian and Caucasian population in the distribution of the pairs of haplotypes 
including the deletion AAG. Thus, differences in 5-HT3B antagonist response between 
Asians and Caucasians can not be ascribed to differences in the frequency of the deletion 
AAG but may be attributable to the differences in haplotype pairs that exist in each 
population. However, the effect of the deletion AAG or its haplotype has never been 
studied in Asian patients in relation to unresponsiveness to 5-HT3 receptor antagonists. 
A limitation of this study is that we used self-reported ethnicity. However, to make a more 
accurate assessment of ethnicity also the ethnicity of the parents and grandparents were 
verified.
In conclusion, Indonesian cancer patients have significant different haplotypes distribution 
of gene encoding the 5-HT3B receptor compared to healthy Caucasians. Since previous 
studies of Tremblay et al.8 and Rueffert et al.9 have suggested that the SNP rs45460698 
(deletion AAG in 5’-UTR position) was predictive for the efficacy of tropisetron and 
ondansetron, we propose that the interethnic differences in 5-HT3B haplotype frequencies 
could result in interethnic differences of response to 5-HT3 receptor antagonists. However, 
this hypothesis should be tested in a prospective study.
Acknowledgements
The authors thank the patients who were participated in this study, and the laboratory 
assistants in the Clinical Pharmacy and Toxicology Laboratory in Leiden University Medical 
Center, Leiden the Netherlands.
The 5-HT3B haplotype frequencies in AsiansChapter 4
64
Financial support
This work was supported by the Netherlands Organization for International Cooperation 
in Higher Education (Nuffic). 
REFERENCES
1. Walstab J, Hammer C, Bonisch H, Rappold G, Niesler B. Naturally occurring variants in the HTR3B 
gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors. 
Pharmacogenet Genomics 2008; 18:793-802.
2.  Hardman J, Limbird L, Gilman A. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 
New York: McGraw-Hill Medical Publishing Division; 2010. 
3.  Niesler B. 5-HT(3) receptors: potential of individual isoforms for personalised therapy. Curr Opin 
Pharmacol 2011.
4.  Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. 
Pharmacogenomics 2008; 9:501-504.
5.  Frank B, Niesler B, Nothen MM, et al. Investigation of the human serotonin receptor gene HTR3B 
in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004; 
131B:1-5.
6.  Tanaka M, Kobayashi D, Murakami Y, et al. Genetic polymorphisms in the 5-hydroxytryptamine 
type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11:261-
267.
7.  Yamada K, Hattori E, Iwayama Y, et al. Distinguishable haplotype blocks in the HTR3A and HTR3B 
region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol 
Psychiatry 2006; 60:192-201.
8.  Rueffert H, Thieme V, Wallenborn J, et al. Do variations in the 5-HT3A and 5-HT3B serotonin 
receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting? Anesth 
Analg 2009; 109:1442-1447.
9.  Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene 
as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21:2147-
2155.
10.  Crawford D, Nickerson D. Definition and clinical importane of haplotypes. Annu Rev Med 2005; 
56:303-320.
11.  Meineke C, Tzvetkov MV, Bokelmann K, et al. Functional characterization of a -100_-102delAAG 




T3B haplotype frequencies in Asians
Chapter 4
The 5-HT3B haplotype frequencies in AsiansChapter 4
66
Translation and validation 
of EORTC QLQ-C30 












Jpn J Clin Oncol 2011; 41(4):519-529.
5
ABSTRACT
Objective: Quality of life studies in Indonesia are still uncommon. This research was 
aimed to validate the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire – C30 (EORT QLQ-C30) in an Indonesian version. The 
standard procedure of forward-backward translation was adhered to in the translation 
procedures. The validity procedure included reliability, convergent and discriminant 
validity, known-groups validity, factor analysis and external convergent validity.
Methods: Data were collected from cancer patients in the Oncology Department of 
Sardjito Hospital, Yogyakarta, Indonesia, who were treated with cisplatin at the dosage 
≥ 50 mg/m2 as monotherapy or in combinations. The Short Form-36 to assess the 
external convergent validity of our translated questionnaire.
Results: One hundred twenty-eight patients with different cancer diagnoses were 
recruited in the validation process from March 2009 to November 2009. The internal 
consistency with values of > 0.70 was observed in the Indonesian version of the EORTC 
QLQ-C30 scales. All items in the questionnaire met the criteria of convergent and 
discriminant validity, except for items 5. Both of the EORTC QLQ-C30 and the SF-
36 showed that different diagnoses were associated with a similar impact on quality 
of life. Factor analysis showed that only the role function and social function loaded 
onto the second factor together. Correlations between the Indonesian versions of both 
questionnaires were moderate: between 0.18 and 0.48 for the physical, emotional, social, 
fatigue and pain domains.
Conclusions: The Indonesian version of the EORTC QLQ-C30 can be used as 
a questionnaire to assess quality of life in Indonesian cancer patients with high-
emetogenic treatments.
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BACKGROUND 
Cancer and the side effects of cancer treatment are often associated with reduced quality of 
life (QoL).1 Although advances in cancer treatment could improve the outcome of therapy 
in cancer patients, such as survival rate and disease-free conditions, patients continue to 
experience a major impact of cancer and its treatment on numerous physical and psychosocial 
conditions. This may consequently affect the patients’ normal patterns in their social activities, 
psychosocial and spiritual well-being.2-4 Combining treatment strategy with QoL assessment, is 
considered necessary. In modern cancer care, the views of patients are key in cancer treatment 
and patient reported outcomes assessment is the future trend in cancer therapy. Moreover, 
QoL assessment is required to consider the impact of cancer treatment on functional and 
psychosocial health of patients.2 The researches of  instrument development to measure cancer 
patients’ QoL have been developed in many countries and they are published annually.3 
Several instruments have been developed to assess QoL in cancer patients in past decades.4 
Combinations of generic and disease specific instruments have been applied to define 
QoL in patients with multipathology. The European Organization for Research and 
Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) has been 
used internationally in “more than 3,000 studies” as a generic questionnaire among cancer 
patients. As stated in the paper by Kleijn and colleagues “this questionnaire has been 
translated into and validated into more than 50 languages”.5 
The EORTC QLQ-C30 and the Medical Outcomes Study Short Form 36 (SF-36) have five 
domains in common: physical function, mental health/emotional function, social function, 
vitality/fatigue, and pain. The two questionnaires are often used to discover the convergent 
validity of the similar constructs between them. A previous study in nonmalignant pain 
used these questionnaires and demonstrated that both of the questionnaires had acceptable 
psychometric characteristics.4
Information about cancer patients’ QoL in the Indonesian population is inadequate. The 
publications in this field are focused on children. A study about health-related quality of 
life in childhood with acute lymphoblastic leukemia suggested that the patients and their 
family should be supported by psychosocial care during the cancer treatments. Psychosocial 
care during cancer interventions could improve patients’ quality of life.6 Consequently, the 
area of quality of life research needs to be developed urgently in Indonesia in order that 
better supportive care during cancer interventions may be proposed.
The limited research on QoL in Indonesia is associated with the unavailability of validated 
questionnaires in Indonesian versions. Therefore, the objective of this study was to translate 







patients. In this study, the SF-36 was used as a gold standard to test the external convergent 
validity of QLQ-C30. The SF-36 questionnaire has been translated into Indonesian version.7 
The reason for using SF-36 as gold standard was that the SF-36 has been used and validated 
in Indonesian version.8-12 The Indonesian version of the EORTC QLQ-C30 encompassed 
translations from the original English versions with forward-backward translation, pilot 
testing, and review. In order to obtain the Indonesian version of SF-36, the reader can 
contact the author. The validity procedure includes reliability, multi-factorial analysis, 
known-groups validity, factor analysis, test-retest validity and external convergent validity. 
PATIENTS AND METHODS
Step 1: Translation procedures
The procedures for translation into the Indonesian language were adapted from Koller 
et al.13 The translation coordinator contacted two experts in the English Department of 
two universities independently to do the forward translation of EORTC QLQ-C30. The 
research coordinator compared the two forward translations and checked them for any 
discrepancies. The discrepancies between the two translations were discussed with the 
translators until we agreed on the single provisional forward translation. Modifications 
were made in this draft to diminish discrepancies and it was adjusted with a view to the 
habits of Indonesian people. The single forward translation was then back translated 
by two native speakers of English independently. The English back translations and the 
original English version were compared with assure that there was no different meaning 
of the questions in the questionnaires. The discrepancies were discussed and resolved until 
agreement within the translation group was reached. 
Step II: Pilot test
The translated version of the EORTC QLQ-C30 was pilot tested in 20 patients, who were 
recruited from a university hospital in Yogyakarta, Indonesia. Inclusion criteria for the pilot 
test were: cancer patients and healthy people; aged 18 years or older; ability to read and 
write standard Indonesian; and willing to participate in the study. The Indonesian version 
of EORTC QLQ-C30 was distributed to the patients before their chemotherapy treatment, 
and to the healthy people. Any difficulties that the patients had experienced with the 
questionnaire were recorded by the researcher during the time the patients completed the 
questionnaire. The patients’ obstacles in understanding and completing the questionnaires 
were reviewed and used to modify the questionnaires by the translation group.
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Step III: Main study
Subjects
The study population was made up of cancer patients in the Oncology Department of Dr 
Sardjito Hospital, Yogyakarta, Indonesia, who were treated with a cisplatin dosage ≥ 50 
mg/m2 as monotherapy or in combined chemotherapy regimens. Patients aged ≥ 18 years 
old with a Karnofsky Index ≥ 50% were included. Exclusion criteria were: patients with the 
presence of nausea or vomiting 24 hours before chemotherapy; use of other anti-emetics, 
benzodiazepines or neuroleptics, or the application of radiotherapy within 24 hours before 
start of chemotherapy and use of opioids within the previous 2 weeks. 
We studied patients with cisplatin as subjects because cisplatin is one of the cytotoxic agents 
which has a severe emetogenic effect and has a significant effect on patients’ quality of life. 
Dr. Sardjito Hospital, Yogyakarta, is a tertiary care public hospital with approximately 750 
beds, and 250 beds among them were third class services. Most of the third class patients 
are supported by government health insurance in public and private hospitals. Nevertheless, 
there are some third class patients who are not supported by government health insurance. 
Thus, these patients could not pay to get good services from a private hospital. This is due 
to the fact that the health services in this hospital are dedicated to poor people. 
Data collection
Patient’s sociodemographic data such as age, sex, education, diagnoses of cancer and 
performance status of patients based on Karnofsky Performance Status (KPS) were collected 
from their medical records. The procedure of the patients’ data collection in the main study 
was done before administration of cytotoxic drugs. After informed consent procedures 
were completed, patients filled out questionnaires a few hours before chemotherapy and 
on day 5 after chemotherapy administration at the hospital. The time of administration 
of the questionnaire was based on a previous study.9 The study was approved by the local 
ethics committee of the Medical Faculty, Gadjah Mada University, Yogyakarta. 
Statistical analysis
Descriptive data are presented with means and standard deviations (SDs). Discrimination 
of the instruments was tested by floor and ceiling effects. Large floor and ceiling effects 
are assumed to show poor discrimination of the instruments. 
The internal consistency of each subscale was assessed by using Cronbach’s alpha coefficient. 







alpha is 0.70 or greater. Multi-trait scaling analysis was used to test the convergent and 
discriminant validity of the EORTC QLQ-C30. Convergent validity was revealed if the 
item-domain correlation was ≥ 0.40, while the requirements for discriminant validity 
were satisfied if the value of correlation coefficients between the item and its own domain 
was higher than other domains. Known-groups validity was evaluated based on different 
diagnoses using T-test or ANOVA-test. Factor analysis was used to extract factors from 15 
indicators of quality of life in EORTC QLQ-C30. Kaiser-Meyer-Olkin (KMO) and Bartlett’s 
Test were tested to know if the data were suitable for factor analysis. The loading criterion 
was set at less than 0.40 of absolute value. Convergence between instruments (external 
convergent validity) evaluates correlations between similar domains of the SF-36 and 
EORTC QLQ-C30. If one domain has a similar underlying construct, it will show a high 
correlation with the other domain. Pearson’s correlation was used to compute construct 
validity. Correlations above 0.40 are considered satisfactory for convergent validity. 
However, if this correlation is too high (> 0.70), it can be caused by different concept 
measurements, or there may be some useful information obtained by including the two 
domains compared to including only one of the domains. Correlation coefficients of > 0.5, 
0.35-0.50 and < 0.35 were considered to represent strong, moderate, and low correlations, 
respectively. The discriminant validity means that scales measuring different constructs 
should have a low correlation, i.e., < 0.40.2-4,14,15 
RESULTS
Step I: Translation and back-translation 
In the Indonesian version of SF-36, some questions were adjusted to Indonesians’ habits 
and occupations. For example: moderate activities such as moving a table, using a vacuum 
cleaner, bowling, or playing golf in item 3b, was translated into “moving a table, cycling and 
working in the garden”, as “using a vacuum cleaner, bowling and playing golf ” are not done 
by most Indonesian people. Another example, in the original version of SF-36, “walking 
more than one mile” in item 3g, was translated into “walking more than 1.6 kilometers”, 
as Indonesian people use “kilometers”. In the first draft of EORTC QLQ-C30, the medical 
words such as insomnia, constipation and depression were translated into non-medical 
word such as, difficult to sleep, difficult to defecate and feeling stress.
There were some differences in the back-translations of the questionnaire but the translators 
were of the opinion that the differences would not change the meaning of word, because 
the Indonesian language has less vocabulary than the English language. The differences in 
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expression of the response choices of the Likert-type scales were also present between the 
back-translation versions and the original version. But the translators were of the opinion 
that the differences were only about the formal style of the language and would not change 
the meaning of the expression. Therefore, the expression of the response choices used the 
less formal style which is appropriate with the lower and middle levels of education in 
these cancer patients. 
Step II: Pilot test
Twenty people (10 healthy people and 10 cancer patients) were enrolled in the pilot test. 
The age range for the healthy people varied from 19 to 49 years with a mean of 26.10 years 
(SD = 8.88); the age range of cancer patients varied from 26 to 63 years with a mean of 
49.60 years (SD = 9.83). The average completion time of translated version of the EORTC 
QLQ-C30 were 4.54 min (SD = 1.00) for healthy people and 5.88 min (SD = 1.97) for cancer 
patients. Most patients were able to fill out the questionnaires by themselves, except for 
items 29 and 30 in EORTC QLQ-C30, where the patients needed an explanation about the 
meaning of the quality of life in the less formal language style and about the differences 
between items 29 and 30. Item 29 in EORTC QLQ-C30 asks the patients to rate their overall 
health during this past week, whereas item 30 asks the patients to rate their quality of life. 
Generally, the subjects asked about the meaning of quality of life or asked to the researcher 
to give a short description about quality of life.
Step III: Main study 
Patients’ demographic data
One hundred and twenty eight patients were recruited in this study from March 2009 to 
November 2009. Patients had different diagnoses of cancer. The most prevalent diagnostic 
category was cervical cancer. Out of 57% cancer patients had KPS of < 90%, which means 
that more patients needed some efforts to carry on normal activity with some signs or 
symptoms of cancer than patients with normal activity and minor signs or symptoms 
of cancer. When we dichotomized the sample on the basis of KPS < 80 and 80-100 (n = 
118), we found that the number of patients in the < 80 group was 10 and the number of 
patients in the 80- 100 group was 118. Furthermore, sensitivity analyses regarding this 
point by for instance dichotomizing the sample in < or ≥ than 70 on the KPS would run 
into difficulties as that would imply comparing n = 4 (for KPS < 70) with n = 124 (for KPS 
≥ 70). The demographic data of the patients are shown in Table 5.1. In regard to educational 







educational level experienced by most of the patients in Dr. Sardjito Hospital where the 
services of this public hospital are dedicated to poor people.
Discrimination and internal consistency
Table 5.2 lists floor and ceiling effects of EORTC QLQ-C30 and SF-36.
The large floor and ceiling effects were found in single items, emotional function and 
cognitive function of EORTC QLQ-C30 (0.8% to 92.2%). Whereas, the large floor and 
ceiling effects in SF-36 were seen on physical and emotional roles (11.1% to 76.2%).
The physical and role functions in SF-36 and the pain, fatigue and single items in EORTC 
QLQ-C30 were questionable following psychometric analysis (mean and SD), i.e., mean: 
16.5 and SD: 33.3 in the physical role domain of the SF-36.
Cronbach’s alpha coefficients are presented in Table 5.2 for all domains of the two 
questionnaires. This study found that for the SF-36 values above 0.70 were observed in 
following domains: physical function, social function, pain, physical role, and emotional 
role. In EORTC QLQ-C30, those five domains were also valued above 0.70. This finding 
means that for those five domains, EORTC QLQ-C30 has the same reliability as SF-36. 
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Table 5.1 Sociodemographic data of the patients
SD, standard deviation; KPS, Karnofsky Performance Status.
n %
Age, years (n = 128)
Mean (SD) 47.6 (10.5)
Range 22-70
Sex (n = 128)
Male 9 7.0
Female 119 93.0
Education (n = 128)
No schooling 46 35.9
Elementary school 35 27.3
High school 36 28.1
Undergraduate  7 5.5
Diagnosis of cancer (n =128)
Cervical cancer 77 60.1
Ovarian cancer 35 27.4
Others 16 12.5
KPS
< 90% 73 57.0
90-100% 55 43.0
Furthermore, in EORTC QLQ-C30 the values above 0.70 were not only observed in those 
five domains, but also in all domains. We excluded the outlier factor in the cognitive 
function to get a better value of Cronbach’s alpha.
Multi-trait analysis
Table 5.3 shows that the convergent validity was revealed due to all of the value of coefficient 
correlations between the item and its own domain were ≥ 0.40, except for items 5, 10, 15 
and 25. Table 5.3 also shows that all items meet the discriminant validity criterion except 







Table 5.2 Means, floor and ceiling effects, and Cronbach’s α coefficients of the domains in the 
QLQ-C30 and SF-36
Domain Mean SD Floor (%) Ceiling (%) Cronbach’s α coefficient
QLQ-C30
Physical function 74.0 21.8 1.6 23.0 0.82
Role function 63.3 24.0 3.2 12.7 0.79
Emotional function 93.5 12.2 0.8 68.3 0.78
Social function 65.8 23.7 0.8 17.5 0.83
Cognitive function 93.8 14.3 0.8 79.4 0.82
Global QoL 58.7 16.4 0.8 2.4 0.80
Pain 34.5 26.5 24.6 3.2 0.85
Fatigue 30.2 21.6 15.1 0.8 0.72
Nausea and vomiting 12.4 21.9 68.3 0.8 0.70
Dyspnea 5.2 18.5 91.3 1.6 Single item
Insomnia 32.4 30.7 39.7 4.0 Single item
Appetite loss 20.0 28.5 60.3 4.0 Single item
Constipation 17.6 27.4 65.1 3.2 Single item
Diarrhea 3.9 15.5 92.1 1.6 Single item
Financial difficulties 42.2 29.6 22.2 7.1 Single item
SF-36
Physical function 63.9 25.1 1.6 9.5 0.82
Mental health 75.3 18.1 0.8 9.5 0.66
Social function 65.8 23.7 1.6 11.1 0.70
Energy 63.8 18.9 0.8 5.6 0.60
Pain 63.1 29.4 0.8 21.4 0.87
General health 55.3 15.8 0.8 0.8 0.60
Physical role 16.5 33.3 76.2 11.1 0.92
Emotional role 23.2 40.7 73.0 20.6 0.97
QLQ-C30, quality of life core questionnaire; SF-36, Study Short Form 36; QoL, Quality of Life.
Known-groups validity
The known-groups validity of the two questionnaires among three groups of diagnoses is 
presented in Table 5.4. We measured the five domains between in the EORTC QLQ-C30 
questionnaire, that is, physical function, emotional function, social function, pain, and 
energy/fatigue. There were no significant differences in both EORTC QLQ-C30 when they 
were applied in different diagnoses of cancer (P > 0.05). 
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Table 5.3 Multi-trait scaling analysis of EORTC QLQ-C30
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; 
PF, Physical Function; RF, Role Function; EF, Emotional Function; CF, Cognitive Function; SF, Social Function; FA, 
Fatigue; NV, Nausea and Vomiting; PA, Pain; QL, Quality of Life.
The bold numbers show that the coefficient correlation between the items and its own domain are ≤ 0.40.
The number with * show that the coefficient correlation between the item and other domain is higher than the 
coefficient correlation of the item and its own domain. All the values in the boxes are significantly correlated.
Item 
no
Description PF RF EF CF SF FA NV PA QL
1 Strenous activity -.75 -.41 -.04 -.05 .08 .22 .07 -.01 .03
2 Long walk -.75 -.32 -.11 -.09 .08 .12 -.03 -.02 .09
3 Short walk -.69 -.40 -.09 -.11 -.08 .31 .05 .08 .03
4 Stay in bed/chair -.61 -.30 -.22 -.05 -.03 .43 .17 .15 -.15
5 Needed help in 
eating/dressing/
washing
-.38 -.37 -.45* -.21 -.17 .25 .05 .34 -.13
6 Limited work -.34 -.65 -.25 -.12 -.35 .25 -.06 .28 .09
7 Limited hobbies .-30 -.57 -.18 .02 -.27 .31 .13 .28 -.04
21 Tense -.14 -.17 -.65 -.08 -.25 .14 .10 .25 -.05
22 Worried -.11 -.17 -.64 -.12 -.25 .16 .06 .21 -.08
23 Irritable -.15 -.15 -.54 -.05 -.12 .12 .05 .14 -.10
24 Depressed -.03 -.03 -.49 -.11 -.13 -.12 .01 .13 -.12
20 Concentration -.10 -.09 -.25 -.58 -.07 -.11 -.01 -.26 -.14
25 Memory -.08 -.01 -.01 -.34 -.18 -.04 -.17 .04 -.04
26 Family life .28 -.01 -.12 -.12 -.75 -.03 -.01 .05 -.11
27 Social life -.16 -.33 -.09 -.02 -.71 .17 -.06 .24 .02
10 Need rest -.14 -.17 -.14 -.10 -.21 .28 -.04 .05 -.08
12 Feel weak -.30 -.27 -.29 -.04 -.19 .40 .03 .29 -.10
18 Tired -.34 -.26 -.32 -.11 -.17 .50 .14 .31 -.10
14 Nausea -.08 -.09 -.21 -.02 -.24 -.06 .40 .15 -.15
15 Vomiting -.05 -.11 -.21 -.09 -.19 .13 .34 .14 -.15
9 Pain -.20 -.27 -.26 -.14 -.07 .16 .09 .59 .07
19 Relation of 
pain with daily 
activities
-.29 -.38 -.33 -.19 -.15 .27 .03 .60 -.29
29 Overall physical 
condition
.07 .06 .23 .03 .14 -.07 -.20 -.05 .62
30 Quality of life .14 .07 .25 -.07 .03 -.19 -.22 -.19 .65
Factor analysis
Based on the KMO and Bartlett test, the data was suitable for factor analysis (KMO value 
was 0.708 and Bartlett test was 1.765 x 103, P = 0.000). The extraction of factors was based 
on the criterion of an eigenvalue greater than one that is ten-factor solution with 70.41% 
of total variance. 
Factor analysis results are presented in Table 5.5. All items in each domain loaded 
significantly on one factor of 10 factors. All of the items in physical function, except item 
5, loaded significantly on the first factor. The emotional function items loaded significantly 
on the second factor, except item 23. Pain items loaded significantly on the third factor, 
role function and social function items on the fourth factor, nausea and vomiting items 
on fifth factor, general quality of life items on the sixth factor, fatigue items on seventh 
factor, and cognitive function’ items on the eight factor. Item 23 loaded significantly on 
the ninth factor, and item 5 loaded significantly on the fifth factor.
External convergent validity
The external convergent validity of the questionnaires is presented in Table 5.6. This 
analysis was performed for physical functioning, social functioning, emotional functioning, 
fatigue, and pain.
Moderate correlations (0.35 - < 0.5) were observed in the physical function and pain 
domains, whereas the other functions showed low correlations between the questionnaires 
(P < 0.05). Otherwise all of the discriminant validity in the two questionnaires met the r 







Table 5.4 Scores of the five QoL domains of QLQ-C30 in the cancer diagnosis groups
PF, Physical Functioning; EF, Emotional Function; SF, Social Function; FA, Fatigue; PA, Pain.
* One way ANOVA test or Kruskall-Wallis test.










Cervical cancer 77 (60.1) 72.3 (22.5) 93.9 (11.5) 66.2 (22.5) 31.5 (23.6) 33.9 (26.9)
Ovarian cancer 35 (27.4) 72.7 (21.6) 92.9 (14.5) 68.0 (24.0) 32.2 (19.6) 35.4 (27.9)
Others 16 (12.5) 81.5 (19.9) 90.0 (14.2) 58.2 (27.9) 23.5 (17.1) 40.4 (25.6)
P value* 0.24 0.72 0.46 0.37 0.80

















































































































































































































































































































































































































































































































































































































































































































































































































































































This study showed the acceptable psychometric properties of reliability and validity 
evaluation of EORTC QLQ-C30 in our Indonesian version. This scale development will 
help clinicians to describe the human side of cancer treatment in Indonesia. The practicing 
oncologist can benefit greatly from the work that was performed in developing and 
validating this scale, by applying the instrument to the selection of treatment modalities 
based on both treatment efficacy and the patient’s wishes. In the future, QoL research in 
Indonesia will continue to be integrated into the practice of oncology.
The translation of EORTC QLQ-C30 into the Indonesian language was in compliance with 
the procedures developed by the EORTC Quality of Life Study Group.13 The backward 
translation of the modified items was compared with the original versions and was 
found to be satisfactory. In the pilot study, the cancer patients were able to complete the 
questionnaire in a somewhat longer time than the healthy subjects. This could be due to 
the severity of the diseases which made the patients need more time to focus on completing 
the questionnaires. The patients’ cognitive function in understanding the questionnaires, 
could be affected by multiple and severe symptoms in cancer.16 Nevertheless, all of the 
patients in pilot testing were able to fill in the questionnaire by themselves.
Discrimination in physical function, role function, social function, global quality of life, 
pain and fatigue in EORTC QLQ-C30 were good (i.e., 0.8% for floor effects and 17.5% for 
ceiling effects in social function). However, in the single items, emotional and cognitive 
function showed poor discrimination (i.e., 4.0% for floor effects and 60.3% for ceiling 







Table 5.6 Pearson’s correlation coefficient among the subscales in the Standard Indonesian version 
of SF-36 and QLQ-C30
PF, Physical Functioning; MH, Mental Health; EF, Emotional Function; SF, Social Function; E, Energy; FA, Fatigue; 
PA, Pain. The bold numbers show the significant Pearson’s correlation coefficients between the same subscales 
of the SF-36 and the QLQ-C30.
SF-36 SF-36 SF-36 SF-36 SF-36
PF MH SF E PA
QLQ-C30 PF 0.40 -0.03 0.33 0.21 0.28
QLQ-C30 EF 0.05 0.25 0.20 0.28 0.25
QLQ-C30 SF 0.04 0.07 0.11 0.16 -0.02
QLQ-C30 FA -0.28 0.11 0.36 -0.17 -0.27
QLQ-C30 PA -0.20 -0.20 -0.16 0.27 -0.45
value of the domains. All of the functions in SF-36 showed good discrimination, except 
for physical role and emotional role. Poor ability of patients to distinguish the physical 
and emotional role or the narrow response of these domains could give rise to this poor 
discrimination. All functions with poor discrimination had less than clear descriptions 
of cancer patients’ feelings. 
Poor discrimination and cancer patients’ feeling could be affected by anxiety and depression 
during chemotherapy. Anxiety and depression may result from excessive feelings of distress. 
This psychological distress had significant association with memory and concentration.17 
Indeed, the small sample size could effect the poor discrimination. For example in the 
nausea symptoms, there were 109 patients who answered “not at all”, and the other patients 
answered the other responses. It showed that the patients’ responses were not distributed 
normally in all of the responses. Thus, the floor effect was shown by nausea symptom. A 
larger sample size could result in better distribution responses. Therefore, the interpretation 
of this scale in a broad spectrum of cancer patients must be careful and might need to 
be validated when applying it to other types of cancer. This phenomenon may contribute 
significantly to poor discrimination and descriptive assessments. Ideally, the questionnaires 
should be given 72 hours before the administration of the chemotherapy.9 However, 
the system in this hospital could not trace the patients 2-3 days before administration 
of chemotherapy. As a result, the questionnaires were given only a few hours before 
chemotherapy. Patients’ memory and concentration levels a few hours before chemotherapy 
could be affected by patients’ psychological distress.
Another possible explanation of these results is that certain symptoms (dyspnea, insomnia, 
appetite loss, constipation and diarrhea) were not experienced by the patients, or that 
these symptoms were experienced by the patients but the patients could cope despite 
these symptoms. 
In the SF-36 questionnaires, the internal consistency was somewhat problematic for 
mental health, energy and general health. The low to middle education level of the subjects 
could have affected the internal consistency: the subjects needed more explanation 
about the response options. The Cronbach’s α of EORTC QLQ-C30 was acceptable in all 
scales.
The convergent and discriminant validity of EORTC QLQ-C30 were consistent with the 
results of previous studies. The EORTC QLQ-C30 in simplified Chinese version and in 
Korean cancer patients also met the convergent and discriminant validity.3,18 The low 
coefficient correlation in item 5, 15, 20 and 25 may be caused by the skewed distribution 
of the responses. Out of 93% patients answered “not at all” response for item 5, only 4.7 % 
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of patients answered “very much” for item 10, 93.8% and 91.4% of patients also answered 
“not at all” for item 20 and 25. The previous study in Korean cancer patients also reported 
the same problem.18
In order to examine an additional issue of the psychometric characteristics of the Indonesian 
version of the EORTC QLQ-C30 questionnaire, it was decided to compute known-groups 
validity. The known-groups validity analyses which were performed using different 
diagnoses of cancer showed that there were no statistically significant differences among 
groups. This fact explained that all of the domains in EORTC QLQ-C30 were not better 
in discriminating ovarian, cervical and other diagnoses of cancer. We acknowledge that 
this is just one phase in addressing this issue. Further study should include additional 
questionnaires from samples with varying diagnostic categories of cancer.
The factor analysis showed the satisfactory result that all items in each domain loaded on 
one factor. Only role function and social function loaded on the second factor together. 
This factor described the effect of limited role to social life. 
The external convergent validity correlation between domain of SF-36 and EORTC 
QLQ-C30 values was under 0.70. Physical function and pain had strong correlations 
in both questionnaires. However, the moderate and low correlation coefficient in the 
other domains of SF-36 and EORTC QLQ-C30 suggest that the subscales were assessing 
distinct components of the construct of quality of life. The differences can be explained in 
the physical function of the SF-36 which contains 10 items, while the EORTC QLQ-C30 
only contains five items. In some items SF-36 has more specific questions than EORTC 
QLQ-C30. Nevertheless, the EORTC QLQ-C30 has a broader spectrum of symptoms, such 
as nausea/vomiting, pain, insomnia, dyspnea, appetite loss, constipation and diarrhea. 
The patients had difficulties in completing the questions number 29 and 30 in EORTC 
QLQ-C30. Therefore the instructions of number 29 and 30 were modified to facilitate 
the patients’ understanding. We also gave some explanations to the patients related to 
question number 29 and 30. Another study in China also modified the questions number 
29 and 30 in EORTC QLQ-C30 to increase the patients’ understanding.2 The translation 
procedures of previous studies on EORTC QLQ-C30 in Turkish and Moroccan minority 
ethnic groups in the Netherlands suggested that the “questionnaire was produced for oral 
administration and needed some modifications because of the high illiteracy in Moroccans’ 
first generation in Netherlands”. The subjects in this study also need additional information 
about the meaning of “quality” word.19 Results of our study were consistent with the two 
previous studies, especially in the short description of questions number 29 and 30, also 







The high internal consistency of EORTC QLQ-C30 is also consistent with a previous study 
in patients with chronic nonmalignant pain. Generally, the Cronbach’s α values observed 
in this study are higher than those in the patients with chronic nonmalignant pain.4 The 
low Cronbach’s α value for cognitive function was also found in the previous study with 
various diagnoses of cancer; also homogenous diagnoses of cancer.20,21 Otherwise, the 
other studies in China and Singapore had a lower internal consistency (< 0.70) for physical 
function and cognitive function in various diagnoses of cancer.2,15 The finding in our study 
was consistent across different cultures.
The known-groups validity of the EORTC QLQ-C30 is different from a previous study 
which compared the same instruments. The emotional function, social function and pain 
were significantly different between EORTC QLQ-C30 and SF-36 in the previous study.4 
Future research on this issue is called for.
Factor analysis results of this present study were not consistent with the factor analysis of 
EORTC QLQ-C30 in Korean cancer patients, which showed two factors with more than 
one domain loaded. The “emotional distress” factor was appear because the emotional 
function and cognitive function were loading together in one factor.18 The variability of 
cancer diagnoses, patients’ supportive care and patients’ condition during they filled in the 
questionnaire may cause different result of factor analysis among the countries.
The result of convergent validity is also consistent with two previous studies in cancer 
patients, where the convergent validity coefficient values ranged from 0.47-0.74 and 
0.40 to 0.68.22,23 Conversely, the study in cancer patients with chronic pain showed that 
the coefficients values ranged from 0.70 to 0.80.4 The correlation coefficients of pain 
symptoms in cancer diagnoses were lower than those in chronic non-malignant pain 
patients. This finding illustrates that the pain level in cancer diagnoses is less important 
than those of chronic non malignant pain. The other symptoms could have important 
impacts on QoL, such as nausea and vomiting. Otherwise, the correlation coefficients 
between mental and physical function, energy and mental function in cancer patients 
were higher than those in chronic non malignant pain patients. Results showed that the 
correlation of physical and mental functioning in cancer patients is more important than 
the coefficient correlation of physical and mental function in chronic non-malignant pain. 
Another study in Germany indicated that patients had different interpretations of health 
subscales of EORTC QLQ-C30, SF-36 and Functional Living Index Cancer Questionnaire 
(FLIC), even though all three questionnaires had convergent validity in physical function, 
emotional function, pain, fatigue and nausea/vomiting. These results were caused by the 
different views of QoL in three questionnaires.23 
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The convergent validity in our study was consistent with another study of questionnaire 
validation which was done in Indonesia between Nepean Dyspepsia Index (NDI) and 
SF-36. This research also showed low and moderate correlation between the functions in 
both questionnaires (0.036-0.638) with P < 0.05.8
A limitation of our study is the relatively small and unequal sample size in each disease 
group. Even though the sample size was small and unequal, we believe that this study is still 
valid and relevant, because all of the domains in the EORTC QLQ-C30 were reliable and 
met the convergent validity, construct validity and test-retest validity. We also supported 
the validation analysis with factor analysis which showed that every domain in the EORTC 
QLQ-C30 loaded significantly on one factor. A larger sample size of patients with each type 
of cancer will facilitate conclusions on how different types of cancer may affect patients’ 
responses to the questionnaires. 
The result of this scale development process could be applied to hospitalized patient. 
Moreover, the scale that we developed may be limited to those patients treated with 
cisplatin. For the time being, our study results will be used in future to study QoL only 
for high-emetogenic cancer treatment. At the same time, we would like to point out that 
the sample size in our study as such is not uncommon in related research. 
Conclusion
In conclusion, this study provides an Indonesian version of the EORTC QLQ-C30 and SF-36 
questionnaires. Despite the fact that overall psychometric properties of both instruments 
were acceptable, this study indicates the further development of the instruments in an 
Indonesian version is required to achieve ideal tools to measure psychometric properties. 
The results of the present study should be confirmed in a study with an increased sample 
sizes. 
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APPENDIX
Indonesian version of EORTC QLQ-C30
Kami ingin mengetahui beberapa hal yang berkaitan dengan Anda dan kesehatan Anda. Jawablah semua 
pertanyaan dengan melingkari angka yang paling sesuai. Tidak ada jawaban “salah” atau “benar”. Informasi yang 
Anda berikan akan dirahasiakan.
Tidak Sedikit Sering Sangat Sering
1 Apakah Anda mengalami 
kesulitan saat melakukan 
kegiatan yang berat, 
seperti membawa barang 
belanjaan atau koper 
yang berat?
1 2 3 4
2 Apakah Anda mengalami 
kesulitan jika berjalan 
kaki dalam jarak yang 
jauh?
1 2 3 4
3 Apakah Anda mengalami 
kesulitan saat berjalan 
kaki meskipun dalam 
jarak yang pendek, 
misalnya di sekitar rumah 
Anda?
1 2 3 4
4 Apakah setiap hari 
Anda harus berbaring di 
tempat tidur atau duduk 
di kursi ?
1 2 3 4
5 Apakah Anda 
memerlukan bantuan 
orang lain saat makan, 
berpakaian, mandi atau 
buang air?
1 2 3 4
Dalam seminggu 
terakhir:
Tidak Sedikit Sering Sangat Sering
6 Apakah Anda mengalami 
keterbatasan saat bekerja 
atau melakukan kegiatan 
sehari-hari lainnya,?
1 2 3 4
7 Apakah Anda mengalami 
keterbatasan saat 
melakukan kegiatan 
santai atau kegiatan yang 
merupakan hobi Anda?
1 2 3 4
Dalam seminggu 
terakhir:
Tidak Sedikit Sering Sangat Sering
8 Apakah Anda merasa 
sesak nafas?
1 2 3 4
9 Apakah Anda merasa 
nyeri?
1 2 3 4
10 Apakah Anda perlu 
beristirahat?
1 2 3 4
11 Apakah Anda sulit tidur? 1 2 3 4
12 Apakah Anda merasakan 
badan Anda lemah?
1 2 3 4
13 Apakah Anda kehilangan 
nafsu makan?
1 2 3 4
14 Apakah Anda merasa 
mual?
1 2 3 4
15 Apakah Anda muntah? 1 2 3 4
16 Apakah Anda sulit buang 
air besar?
1 2 3 4
17 Apakah Anda diare? 1 2 3 4
18 Apakah Anda kelelahan? 1 2 3 4




1 2 3 4
20 Apakah Anda sulit 
berkonsentrasi pada 
sesuatu hal, seperti 
membaca koran atau 
menonton televisi?
1 2 3 4
21 Apakah Anda merasa 
tegang?
1 2 3 4
22 Apakah Anda merasa 
khawatir?
1 2 3 4
23 Apakah Anda merasa 
mudah tersinggung?
1 2 3 4
24 Apakah Anda merasa 
depresi?
1 2 3 4
25 Apakah Anda mengalami 
kesulitan untuk 
mengingat sesuatu?









Tidak Sedikit Sering Sangat Sering
26 Apakah kehidupan 
keluarga Anda terganggu 
oleh kondisi fisik atau 
terapi medis yang Anda 
jalani?
1 2 3 4
27 Apakah aktivitas sosial 
Anda terganggu oleh 
kondisi fisik atau terapi 
medis yang Anda jalani?
1 2 3 4
28 Apakah Anda mengalami 
kesulitan keuangan 
akibat kondisi fisik 
atau terapi medis yang 
dialani?
1 2 3 4
Untuk pertanyaan-pertanyaan berikut ini, lingkari angka yang paling sesuai.
29 Bagaimanakah Anda menilai kondisi kesehatan Anda secara keseluruhan selama seminggu yang 
lalu?





30 Bagamanakah Anda menilai kualitas hidup Anda selama seminggu yang lalu?
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Impact of chemotherapy induced
nausea and vomiting on quality
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ABSTRACT
Background: Quality of Life (QoL) has become a major outcome in the treatment of 
patients with cancer. This study is aimed at examining the impact of chemotherapy-
induced nausea and vomiting on QoL of patients with gynecological cancer in Indonesia.
Methods: . Chemotherapy-naive patients with gynecological cancer, who were treated 
with cisplatin at a dosage ≥ 50 mg/m2 as monotherapy or as part of combination 
chemotherapy regimens, were recruited in the Oncology Department, Dr. Sardjito 
Hospital, Yogyakarta, Indonesia. QoL was assessed by using the Indonesian version 
of EORTC QLQ-C30 and SF-36, administered immediately before and on day 5 after 
chemotherapy administration. Patients used a daily diary to record nausea and vomiting 
over 5 days after chemotherapy.
Results: Most (74.9%) of the 179 patients experienced delayed emesis during the 5 
days after chemotherapy despite prophylactic use of antiemetics. The delayed nausea 
and emesis caused significant negative impact on patients’ QoL. Nausea in the delayed 
phase caused negative effects on patients’ QoL.
Conclusion: Patients reported negative impact on QoL of delayed emesis after 
chemotherapy. Poor prophylaxis of patients’ nausea and vomiting after chemotherapy 
interferes with patients’ QoL. Medical and behavioral interventions may help to alleviate 
the negative consequences of chemotherapeutic treatment in patients with gynecological 
cancers treated with suboptimal antiemetics.
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INTRODUCTION 
In recent decades, quality of life (QoL) has increasingly become an important outcome in 
the treatment of patients with cancer. In QoL research, the impact of the illness itself and 
the cancer treatments are assessed from the patients’ perspective. One of the factors most 
seriously impacting patients’ QoL during cancer treatment is chemotherapy-induced 
nausea and vomiting (CINV), especially when it is inadequately treated by antiemetic 
drugs.1 Patients may experience acute or delayed CINV during cancer treatment. Acute 
CINV is defined as nausea and vomiting episodes which persist during the first 24 
hours after chemotherapy administration.2 Delayed CINV starts after the first 24 hours 
following chemotherapeutic treatment and may persist up to 120 hours.3 Patients who 
experience both acute and delayed CINV have worse QoL compared with patients 
with delayed CINV only, or without acute and delayed CINV.1 By using an appropriate 
prophylactic antiemetic regimen, the incidence of CINV can be substantially reduced. 
However, despite the availability of highly effective antiemetic drugs, about 20-30% 
of the patients treated with highly emetogenic regimens still experience nausea and 
vomiting. This is caused by the presence of some risk factors, such as gender, age and 
individual susceptibility.4 Health professionals often underestimate the incidence and 
prevalence of CINV.5 
Most gynecological cancer types are treated with highly emetogenic chemotherapeutics, 
such as cisplatin, carboplatin, paclitaxel and cyclophosphamid when paclitaxel is not 
available.6 These drugs are reported to cause emesis in more than 90% of patients without 
prophylactic use of antiemetics7 and may seriously impact QoL. In addition to CINV, the 
psychological distress after cancer diagnosis, especially issues concerning femininity, body 
image, sexuality and reproduction also have been demonstrated to result in a decrease of 
the patients’ QoL.5,8
The incidence of cervical cancer in Indonesia is 13.7 per 100,000 women.9 Despite this 
high incidence, information about the patients’ QoL is still very limited. Therefore, we 
undertook this study to assess the QoL in gynecological cancer patients after treatment 
with highly emetogenic chemotherapeutics, using the European Organization for 
Research and Treatment (EORTC) for Cancer of Quality of Life Questionnaire (EORTC 
QLQ-C30) as a disease specific instrument and the Short Form-36 questionnaire 
(SF-36) as a generic instrument for QOL or functional status. Patients’ QoL baseline 
condition was also determined to know the change of patients’ QoL after treatment with 










The study sample consisted of chemotherapy-naive patients with cervical cancer (n = 
120), ovarian cancer (n = 51), uterine cancer (n = 8) and vulvar cancer (n = 7) in the 
Oncology Department of Dr. Sardjito Hospital, Yogyakarta, Indonesia. They were treated 
with cisplatin at a dosage ≥ 50 mg/m2 as monotherapy or in combination chemotherapy 
regimens. Patients with all diagnoses of gynecological cancer and limited to pelvic or 
advanced  stage of cancer were allowed to be included. Patients were referred by the 
general practitioners to the Dr. Sardjito hospital, Yogyakarta after the diagnosis was made. 
The staging procedures consisted of physical examination by a gynecologist and limited 
imaging when appropriate. Patients in the surgery consideration were treated according 
to the medical standard in Indonesia.
According to the standard of prophylactic antiemetic drug in the hospital, all patients were 
treated in the outpatient clinic by 8 mg intravenous ondansetron, and 8 mg intravenous 
dexamethasone 1 hour before cisplatin administration as a prophylactic antiemetic regimen. 
All patients were also given oral metoclopramide 10 mg, three times a day, from day 2 to 
day 5, to prevent delayed emesis. 
Patients aged ≥ 18 years old with a Karnofsky Index ≥ 50% were included. Patients 
with nausea or vomiting 24 hours before chemotherapy, use of other antiemetics than 
ondansetron and dexamethasone, use of benzodiazepines or neuroleptics, treatment with 
radiotherapy within 24 hours before the start of chemotherapy and the use of opioids 
within the previous 2 weeks were excluded. 
Patients’ socio-demographic data were determined from their medical records. All patients 
gave informed consent. Data collection on demographics and baseline conditions was 
completed before administration of the chemotherapeutic drugs. Patients filled out the 
questionnaires EORTC QLQ-C30 and SF-36 one to four hours before chemotherapy, and 
on day 5 after chemotherapy administration at the hospital. Not all of the patients could 
fill in the questionnaires by themselves, and needed researcher assistance to explain some 
questions, i.e. the questions about general health and general QoL in EORTC QLQ-C30. 
Patients were also asked to fill in a daily diary record to score the  degree of nausea and 
the vomiting frequency during the 4 days after chemotherapy. The study was approved by 
the local ethics committee of the Medical Faculty, Universitas Gadjah Mada, Yogyakarta. 




We used the EORTC QLQ-C30 questionnaire which is available in a validated Indonesian 
translation.10 This original questionnaire was developed by the EORTC for patients with all 
cancer types. The EORTC QLQ-C30 covers basic important personal dimensions in cancer 
patients, in the physical, psychological and social domains. Furthermore, this questionnaire 
also covers cancer symptoms or cancer treatment related symptoms such as nausea, vomiting, 
dyspnea, appetite loss, diarrhea, constipation, insomnia as well as financial impact. The 
questionnaire has been used extensively in many countries to assess QoL of cancer in patients 
in their respective countries.11 The normative data of Dutch population in female subjects was 
used as reference group (n = 796).12 We used the Dutch population as the normative data in 
this study because the normative data of EORTC QLQ-C30 in Indonesian population are not 
available. The characteristics of Dutch subjects who filled in EORTC QLQ-C30 questionnaire 
were female respondents (n = 796) and the mean of aged (± SD) was 50.8 ± 15. Around 63% 
subjects reported the health problems as follow; heart disease, hypertension, asthma/chronic 
obstructive pulmonary disease, diabetes, depression and joint disease.    
SF-36
The SF-36 is a generic instrument which can, therefore, be used in the general population 
and any group of patients with any illness as a generic QoL-instrument.13 The SF-36 has QoL-
dimensions similar to the EORTC QLQ-C30, that is, physical, emotional/mental, social, pain, 
and vitality/energy. In previous studies which compared the SF-36 and EORTC QLQ-C30 in 
patients with cancer, they were found to be satisfactory psychometric instruments in assessing 
consequences of cancer on the physical, emotional, social, pain, and energy dimensions of 
the questionnaire.14 The normative data from Dutch population with age of  45-54 years 
old was used as reference data in this study (n = 180).15 We used the Dutch population as 
the reference because of the collaboration study between the institutions in Indonesia and 
Netherlands and the normative data of SF-36 in Indonesia population are not available.
Delayed emesis
Delayed emesis was defined as delayed nausea and vomiting, as had to be  reported by 
the patients in their diaries. Delayed nausea was measured by the Nausea Visual Analog 
Scale (NVAS) using a severity nausea scale of 0-100.16 Zero on the scale represents ‘no 




oL in patients w
ith CIN
V
indicate the number on the NVAS once daily, over a 4 days period after chemotherapy. The 
frequency of delayed vomiting was defined by asking patients to fill in a daily diary record 
of vomiting frequency. The vomiting episode was defined as single vomiting, and the next 
vomiting episode was defined one minute after the previous vomiting episode.16 The delayed 
emesis was dichotomized into “response”  and “no response”  based on patient’s daily diary 
record. Patients were grouped into “response” if they did not experience nausea on 0 to 25 
scores and did not vomit during 4 days after chemotherapy. Patients were grouped into “no 
response” if they experienced nausea and vomiting during the 4 days after chemotherapy.16 
Statistical analysis
Raw QoL-scores were transformed into  function scales which ranging from 0-100. On 
the EORTC QLQ-C30,  higher scales scores on the dimensions indicate better function, 
i.e. better QoL. Higher scores in symptoms indicate more severe symptoms, i.e. lower 
QoL. Symptoms scores are assessed with the EORTC QLQ-C30, while dimension scores 
of the functioning are measured with both EORTC QLQ-C30 and SF-36. Higher scores 
on the SF-36 indicate better QoL, except for fatigue and bodily pain where higher scores 
indicate more severe symptoms.
Descriptive data are presented as means and standard deviations (SDs). The differences of 
patients’ QoL before and after chemotherapeutic treatment were analyzed using Student’s 
T-test. The differences in functions  and scales between the two groups of delayed emesis 
were defined by independent T-test. P < 0.05 was considered statistically significant. 
RESULTS
Patient characteristics are summarized in Table 6.1. Of the 186 female cancer patients, 
64.5% had cervical cancer, 27.4% had ovarian cancer, 4.3% had uterine cancer and 3.8% 
patients were diagnosed with vulva cancer.  The mean age of patients was 48.3 ± 19.8 years. 
Most of the patients had graduated from high school (34.4%) while 32.3% of patients did 
not have formal education. Comorbidity was present in 15.6% of patients with one disease 
and 0.5% of patients with two diseases.
The available cytostatic for the patients in this hospital were cisplatin, cyclophosphamid, 
doxorubicin and 5FU. In the cervical cancer group, most of the patients who had limited 
pelvic cervical cancer (73.3%) were treated with cisplatin as single agent or in combination 
with 5-fluorouracil, although this is not a standard schedule. The dose of cisplatin as 
single agent was 70 mg/m2 every 3 weeks, while the dose of cisplatin was 50 mg/m2 in 
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combination with 500 mg/m2 of 5-fluorouracil every week. In the ovarian cancer group 
limited stage (62.0%) the treatment consisted of 500 mg/m2 of cyclophosphamide, 50 mg/
m2 of adriamycin and 50 mg/m2 of cisplatin every 3 weeks. 
The baseline QoL scores of all subjects are listed in Table 6.2. We compared the baseline 
QoL in this data with the reference studies.12,15 For this comparison, we have relied on a 
publication,12 for which the raw data were not available for us. As a result is was not possible 
to adjust this comparison for confounding factors with a multivariate analysis. In the 
EORTC QLQ-C30, the functions score of this present study in both of the questionnaires 
were lower than those in reference studies, except for emotional function and cognitive 
function. Meanwhile, the symptoms scores such as pain, fatigue, nausea and vomiting, 
sleeping difficulty, appetite loss and constipation were higher than those of reference studies. 
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Table 6.1 Patient characteristics
* Missing data lead to some minor differences in some of the categories.
Patients characteristics
Age (n = 181) 48.3 (mean) 19.8 (SD)
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The significant differences of function scores were shown by all functions and symptoms, 
except for emotional function, nausea and vomiting and diarrhea (P < 0.001). Moreover, 
the Indonesian cancer patients faced higher financial difficulty than the Dutch population. 
In the SF-36, the Indonesian cancer patients showed significantly lower functions and 
symptoms than those of reference study (P < 0.05).
Seven patients died in this study during the delayed phase, due to their cancer. Most 
patients (74.9%) experienced delayed emesis in the 4 days following chemotherapy, that 
is, a response to the attempt to prevent nausea and vomiting. The patients’ functions in the 
baseline and post chemotherapy based on the patients’ response are presented in Figure 
6.1. At baseline, no significant differences between the response group and no response 
groups were found for any of the QoL domains and symptoms scale.
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Table 6.2 Comparison of baseline patients’ quality of life in this study and the reference studies
Baseline of this study
(Mean ± SD)
Baseline of the reference data
(Mean ± SD) 12;15
P value
EORTC QLQ-C30 n = 186 n = 796
General QoL 60 ± 15 77 ± 18 < 0.001
Physical function 77 ± 20 89 ± 17 < 0.001
Role function 68 ± 25 87 ± 22 < 0.001
Emotional function 94 ± 12 88 ± 17   0.004
Cognitive function 95 ± 10 92 ± 16 < 0.001
Social function 72 ± 23 93 ± 18 < 0.001
Pain 33 ± 25 18 ± 24 < 0.001
Fatigue 25 ± 21 20 ± 21 < 0.005
Nausea vomiting 5 ± 13 3.9 ± 13   0.300
Dyspnea 5 ± 14 7.6 ± 18 < 0.001
Sleeping difficulty 32 ± 30 17 ± 26 < 0.001
Appetite loss 18 ± 25 4.4 ± 14 < 0.001
Constipation 13 ± 24 6.5 ± 17 < 0.001
Diarrhea   4 ± 26 3.8 ± 14   0.942
Financial difficulty 48 ± 48 3.6 ± 13 < 0.001
SF-36 n = 186 n = 180
General health perceptions 52.9 ± 15.2 71.6 ± 23.0 < 0.001
Physical function 51.1 ± 30.6 79.9 ± 24.7 < 0.001
Physical role functioning 30.0 ± 40.9 78.9 ± 37.0 < 0.001
Emotional role functioning 32.8 ± 43.5 83.6 ± 33.1 < 0.001
Mental health 63.2 ± 22.8 76.7 ± 19.6 < 0.001
Social function 54.1 ± 22.0 86.1 ± 21.8 < 0.001
Bodily pain 58.2 ± 27.5 80.5 ± 26.7 < 0.001
Fatigue 61.2 ± 18.9 67.5 ± 20.3   0.002
Health change 42.8 ±  28.7 51.9 ± 19.8 < 0.001
Values are means (SD). The bold P values show the significant differences of baseline QoL scores between this 
study and the reference studies.
On the EORTC QLQ-C30, the patients’ functions did not change much or even deteriorated 
after the chemotherapy. Fatigue was experienced by both response group and no response 
group patients (Figure 6.1). Meanwhile, in the SF-36, general health perceptions, emotional 
function and social function were improved after chemotherapy. Figure 6.2 shows the patients’ 
symptoms at baseline and post chemotherapy based on the response and no response groups. 
This figure shows that the non-response patients experienced more severe dyspnea, sleeping 
difficulty, appetite loss, and constipation after chemotherapy than at baseline. 
The impact of delayed emesis on QoL dimensions in patients with and those without 
a response is presented in Table 6.3. Significant differences between the two groups in 
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Figure 6.1 Patients’ scores on the EORTC QLQ-C30 and SF-36 at baseline and post-chemotherapy 
in responders and non-responders. GQL, General QoL; PF, Physical Function; RF, Role Function; EF, 
Emotional Function; CF, Cognitive Function; SF, Social Function; Fa, Fatigue; Pa, Pain; GH, General 
Health; PR, Physical Role; EP, Emotional Problem.
Group: 
Baseline    
 Post chemotherapy-no response   
 Post chemotherapy-response group  
Q
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symptoms, such as fatigue, nausea, vomiting, and appetite loss were found on the EORTC 
QLQ-C30 questionnaire. The “no response” patients experienced more severe symptoms 
than “response” patients in whom the attempted prevention of nausea and vomiting was 
effective, according to the diary data. Significant differences between the two groups on 
QoL dimensions, such as physical function, mental function, social function and bodily 
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Figure 6.2 Patients’ symptoms on the EORTC QLQ-C30 at baseline and post chemotherapy, for 
responders and non-responders.
Group: 
Baseline    
 Post chemotherapy-no response   
 Post chemotherapy-response group  
pain were also found using the SF-36 questionnaire. The dimensions score show that “no 
response” patients had lower QoL than “response” patients.
This study also found that both the response and no response groups showed the score 
deterioration in most of the dimensions and experienced worse symptoms compared to the 
baseline score (Table 6.3). Other factors which could have a negative impact on patients’ 
QoL are patients’ characteristics such as comorbidity, cancer diagnosis and stage of cancer. 
Meanwhile, only comorbidity showed significant impact on the physical function, pain 
and fatigue symptoms (data are not presented).
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Table 6.3 Mean and standard deviation (SD) of QoL functions 5 days after chemotherapy, based 
on delayed emesis










General QoL 58.4 ± 17.5 58.4 ± 16.4 0.979
Physical function 71.6 ± 24.3 70.0 ± 22.1 0.673
Role function 66.6 ± 24.2 64.5 ± 24.8 0.590
Emotional function 93.9 ± 15.3 93.7 ± 13.2 0.956
Cognitive function 93.3 ± 16.3 92.7 ± 14.7 0.799
Social function 70.3 ± 19.9 72.1 ± 22.7 0.592
Pain 26.1 ± 24.6 31.9 ± 25.1 0.142
Fatigue 34.1 ± 22.2 41.3 ± 20.9 0.032
Nausea vomiting 21.7 ± 25.8 47.3 ± 25.2 <0.001
Dyspnea   5.0 ± 16.0   6.2 ± 16.2 0.650
Sleeping difficulty 27.2 ± 29.1 33.9 ± 28.2 0.140
Appetite loss 30.0 ± 31.1 48.2 ± 28.0 <0.001
Constipation 11.7 ± 24.4 18.5 ± 38.9 0.218
Diarrhea   5.0 ± 17.2   5.0 ± 34.6 0.993
Financial difficulty 35.6 ± 25.2 38.9 ± 27.2 0.423
SF-36
General health perceptions 62.4 ± 20.5 59.1 ± 19.3 0.121
Physical function 57.6 ± 31.4 46.1 ± 32.4 0.025
Physical role function 23.8 ± 39.4 27.9 ± 39.6 0.504
Emotional role function 31.7 ± 45.3 25.5 ± 41.3 0.362
Mental health 77.4 ± 33.1 65.9 ± 30.9 0.024
Social function 63.3 ± 24.6 53.2 ± 21.3 0.005
Bodily pain 69.8 ± 27.4 60.8 ± 25.9 0.034
Fatigue 64.6 ± 19.1 61.3 ± 17.4 0.241
Health change 57.9 ± 33.1 51.1 ± 24.9 0.287
Q




Our results show that, despite optimal initial prophylactic use of antiemetics followed by 
suboptimal prophylaxis for delayed nausea and emesis, most patients with gynecological 
cancer experience delayed emesis. We have to take into account that the standard of 
prophylactic antiemetic drugs which is used at our hospital is suboptimal. Despite this 
shortcoming we decided to study the relationship of CINV and QoL.  
A previous study showed that around 70% of patients  receiving chemotherapy in a 
community hospital  experienced delayed emesis.17 The present study shows a similar 
percentage of subjects experiencing delayed emesis (i.e., 74.9%). All patients were treated 
by a standard antiemetic regimen consisting of ondansetron and dexamethason one hour 
before the cisplatin treatment. Due to the cost of further ondansetron with dexamethason 
and certainly apepritant, suboptimal therapy with oral metoclopramide was prescribed for 
delayed emesis/vomiting. Based on the international guidelines, ondansetron or ganisetron 
in combination with dexamethasone on day 2 to day 5 should be given after highly 
emetogenic chemotherapy  to prevent delayed emesis.7 All of our patients were treated with 
metoclopramide over 5 days, after cisplatin treatment.  Only 34.3% patients had complete 
response in the delayed phase.  Poor control of patients’ symptoms after chemotherapy 
interfered in our study with patients’ QoL.  In another study the metoclopramide efficacy 
was increased significantly by the augmentation of dexamethasone.18
The delayed emesis in our patient sample led to a significant negative impact on the patients’ 
QoL. Significant impact was illustrated by more severe symptoms, such as fatigue, nausea, 
vomiting, appetite loss and pain after chemotherapy. Interestingly, the patients who did not 
experience delayed emesis also showed a deterioration of QoL. The scores of the various 
QoL-dimensions in EORTC QLQ-C30 questionnaire were lower than those in reference 
groups before the chemotherapy treatment.  The symptom scores were also higher than 
those in the reference groups. This probably indicates that Indonesian gynecologic cancer 
patients have lower QoL and experience more severe symptoms than the same groups in 
the Netherlands before start of chemotherapy, possibly related to the suboptimal treatment 
of delayed nausea/emesis. A recent  study in France  suggested that the deterioration of 
physical function, role function and general health  could be a reason for impaired QoL 
in newly diagnosed cancer patients.19 
The present study showed that delayed emesis affects patients’ symptoms such as fatigue, 
appetite loss and bodily pain. The higher score of the functions in the response group and 
the significant differences of function scores between the group of patients with ‘response’ 
and the ‘no response’ group indicate that delayed emesis interferes with patients’ daily 
QoL in patients with CINVChapter 6
100
function. Both ‘response’ and ‘no response’ groups showed that CINV interferes with 
patients’ QoL. These findings are similar to other studies in cancer patients treated with 
moderately to highly emetogenic chemotherapy, despite the use of antiemetic. In addition, 
acute CINV  affects patients’ QoL even for the patients  who do  not experience nausea 
or vomiting during the delayed phase.20 The patients’ comorbidity should be considered 
as well as a factor which can impact on physical function, pain and fatigue.
In general, patients’ QoL was decreased in our study after chemotherapy compared to 
baseline. These findings are  similar to another study in community oncology setting across 
the US which revealed that chemotherapy-induced nausea and vomiting significantly 
interferes with patients’ QoL.1 Our study included cancer patients who received their first 
chemotherapy course with various emetogenic chemotherapy schedules.
General health perception, emotional and social function were maintained. This could 
be explained by the role of family and neighborhood support. One characteristic of the 
Indonesian society, especially in the rural area, is that many people come to the patient’s 
house to give psychological support when the patient comes back from the hospital. This 
finding is supported by Noonan,20 who reported  that patients’ QoL was  not only affected by 
the symptoms of cancer and side effect of treatment, but also by the psychosocial condition, 
such as family support.The study on the survivorship in cancer patients suggested that the 
ability to return to family, social and work activities was an essential part of survivorship.21
Another study which used FLIE (Functional Living Index of Emesis) as the QoL 
instrument to study the relationship of CINV and patients’ QoL, revealed that the score 
on FLIE after chemotherapy decreased significantly in the range of 21.6%-24.4%. Patients 
with CINV also had  a decrease of health utility in the range of 15%-6.9%.22 In addition, 
it has been reported that both acute and delayed emesis have significant impact on 
patients’ daily functioning. Furthermore, it is frequently under-reported and untreated, 
since the patients experience these symptoms after they have left the hospital.1 In our 
hospital a similar situation exists as patients leave hospital on average 4 hours after the 
chemotherapy has been given.
Different health care providers in the Western world have variously predicted the 
incidence rates of CINV and their prediction in prescription of antiemetics has also 
varied. For example, in patients receiving highly emetogenic chemotherapy, the use 
of 5-hydroxytriptamine receptor antagonists and dexamethasone as antiemetics led to 
an underestimation by the health providers in predicting delayed emesis.23 In contrast, 
the use of aprepitant in combination with dexamethasone and 5-hydroxytriptamine 
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CINV. Furthermore, it has been suggested that the health care providers increase their 
appreciation of delayed CINV incidence by using structured patients-reported outcome 
instruments.5 
On the basis of the results in the present study, we also recommend that the health care 
providers in Indonesia should closely monitor delayed emesis and prescribe an appropriate 
antiemetic prophylaxis.
The results of our study indicate that poor control of delayed emesis in cancer patients 
treated by highly emetogenic chemotherapy unnecessarily reduces the patients’ QoL. Thus, 
appropriately potent antiemetics should be used to prevent delayed emesis. In clinical 
practice, the oncologist who prescribes chemotherapy in combination with suboptimal 
chemotherapy, should be aware of delayed CINV, since the delayed emesis adversely 
affects patients after they have left the hospital. Furthermore, the delayed emesis should 
be closely monitored to improve the patients’ QoL and patients’ adherence in following 
the next cycles of chemotherapy. Cognitive-behavioural interventions, counseling and 
supportive therapy seem to be additional promising strategies to improve gynecological 
cancer patients’ QoL and their survivorship.1,21 
Conclusion
Patients with gynecological cancer in our study experienced severe symptoms, such as 
fatigue, nausea, vomiting, appetite loss and pain after chemotherapy despite adequate 
prophylactic use of antiemetics for acute nausea and vomiting but with insufficient 
prophylactic antiemetic therapy for chronic nausea and vomiting. These symptoms affected 
other domains as shown in both the EORTC QLQ-C30 and the SF-36 questionnaires.
Poor control of patients’ chronic nausea and vomiting after chemotherapy has a negative 
impact on patients’ QoL. 
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Since chemotherapy-induced nausea and vomiting (CINV) is the most distressing side 
effect of chemotherapy,1 the optimal use of antiemetic drugs for cancer patients has become 
a major goal for health professionals. Although international guidelines recommend the 
combination of a neurokinin-1 antagonist, a 5-hydroxytriptamine 3 receptor antagonist 
(5-HT3RA) and a corticosteroid as a standard antiemetic regimen for cancer patients 
treated with highly emetogenic cytotoxic agents,2 these drugs are not at every Indonesian 
patient’s disposal. First of all, the neurokinin-1 antagonist is not registered and thus not 
available in Indonesia and secondly, 5-HT3RAs are available at a high cost. For patients 
who are covered by the national health insurance the 5-HT3RAs are affordable, however, 
for the 40% of patients who are not covered by the national health insurance, these drugs 
are not affordable.
The suboptimal treatment with antiemetics results in symptoms of acute and delayed nausea 
and vomiting and could interfere with the patients’ daily functions. In addition, patients 
may refuse to continue their cycles of chemotherapy because of CINV.1 The suboptimal 
treatment of CINV in the acute phase can predict the presence of delayed CINV. Both 
acute and delayed CINV have a negative impact to the patients’ quality of life (QoL),3 
but especially delayed CINV is known to be a strong predictor of the deterioration of 
patients’ QoL.1 Therefore, optimal prevention of CINV in the acute phase should be closely 
monitored not only for the acute effects but also to prevent the presence of delayed CINV.
The efficacy of antiemetic drugs in cancer patients is influenced by several factors, such as 
patients’ age, gender, history of previous nausea vomiting and the use of alcohol.2 Moreover, 
the role of genetic polymorphisms in 5-HT3RAs efficacy in Caucasian cancer patients 
has been evaluated.3 Indeed, genetic polymorphisms in genes encoding enzymes and 
transporters involved in drug distribution and metabolism may affect the drugs’ efficacy. 
The 5-HT3RAs inhibit the impulse stimulation which will be transmitted into the 
chemoreceptor trigger zone and vomiting center, after passing through the distribution 
and biotransformation pathways. This stimulation is developed by the interaction of 5-HT3 
receptors and 5-HT3 which is released by the cytotoxic drug.4 The distribution of the 
5-HT3RAs encompasses ABCB1 as a protein uptake transporter in the gastrointestinal and 
central nervous system and OCT1 as a protein uptake transporter in the hepatic cell.7,8 In 
addition, CYP2D6 being one of the cytochrome P 450 subenzymes for oxidative metabolism 
plays a major role in the metabolism of the 5-HT3RAs.5,9 Genetic polymorphisms in the 
genes encoding ABCB1,10 OCT1,5 CYP2D611 and 5-HT3RB, C and D12-14 have indeed 
shown to modify the efficacy of the 5-HT3RAs in preventing the CINV in Caucasian 
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cancer patients. There is a strong biological rationale for such relationships. For example, 
the polymorphisms of the gene encoding CYP2D6 result in intermediate, poor or ultrarapid 
CYP2D6 metabolizer phenotypes and have therefore a significant influence on ondansetron 
and tropisetron’s serum concentrations. Patients with lower ondansetron and tropisetron’s 
serum concentrations experienced more severe nausea and vomiting compared to patients 
with higher ondansetron and tropisetron serum concentrations.11
In this new era of genetic polymorphisms influencing the antiemetics’ efficacy, an emerging 
role of oncology pharmacists in ensuring the appropriateness of the prescription of 
antiemetics can be developed.15 However, further studies are warranted to translate the 
results of pharmacogenetic studies in this field into the clinical oncology practice. Since 
there was only very limited information about antiemetics’ efficacy and impact of the 
genetic polymorphisms on the antiemetics’ efficacy in the Asian population, the studies 
described in this thesis were designed to answer those questions. 
The general aims of this thesis are (1) to optimize the prevention and treatment of CINV 
by exploration of pharmacogenetic biomarkers , and (2) to determine the impact of CINV 
on QoL in Indonesian cancer patients. The association of pharmacogenetic biomarkers and 
antiemetics’ efficacy is described in the first part of this thesis, subsequently the impact of 
CINV to the patients’ QoL is discussed in the second part of the thesis. 
Association of polymorphisms with antiemetics response in Indonesian 
cancer patients after being treated by highly emetogenic chemotherapy 
in community hospital-based setting
In chapter 2, we reviewed the literature on individualization of antiemetic drugs in oncology. 
It was confirmed that the pharmacogenetic studies of antiemetic in oncology were sparse. 
Interpatient variability of the 5-HT3RAs drug response is thought to be caused by genetic 
variation in proteins involved in the biotransformation and transport and pharmacodynamics 
of the drugs. The 5-HT3RAs are substrates of ABCB1 and are metabolized by the CYP2D6 
isoenzyme.10,16 Indeed, some studies in Caucasian cancer patients show that variability of 
the antiemetic response of ondansetron and tropisetron are related to the C3435T variant 
of the ABCB1 gene and to the phenotypes of CYP2D6.10,16 Furthermore, the 5-HT3B and C 
receptor gene variabilities were found to be predictor of ondansetron’s efficacy as well. The 
100_102AAG deletion variant of the 5-HT3B receptor gene and the K163N variant of the 
5-HT3C receptor gene were shown to be related to response upon ondansetron treatment 
in Caucasian cancer patients.12,16,17 However, further studies are warranted to replicate and 
confirm these pharmacogenetic associations regarding the 5-HT3RAs. 
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One cannot simply translate the findings of pharmacogenetic studies in one ethnic group 
to another. One reason is that allele frequencies of genetic variations may greatly vary 
among ethnicities. Therefore, the findings of the studies described in chapter 2, which were 
performed in Caucasian cancer patients, may not by definition hold true for Indonesian 
cancer patients. To explore the potential of these findings in Indonesian cancer patients we 
started with comparing allele frequencies of variants in the 5-HT3B receptor gene between 
Caucasians and Indonesians. 
The haplotypes frequencies of the gene encoding 5-HT3B receptor in Indonesian cancer 
patients and Caucasian healthy subjects are compared in chapter 4. The frequencies 
of AAGAG and AAGGG haplotypesin the gene encoding 5-HT3B receptor between 
Indonesians and Caucasians differ significantly (OR = 1.50; 95% CI: 1.18-1.90 and OR = 
0.58; 95% CI: 0.58-0.79, respectively). The frequency of AAGAG haplotype in Indonesians 
is higher than those in Caucasians, however, the frequency of AAGGG haplotype in 
Indonesians is lower than those in Caucasians. This finding can be used to understand 
interethnic variation of disease and drug response related to the 5-HT3B receptor. However, 
in pharmacogenetic studies regarding the 5-HT3B receptor gene, the deletion AAG variant 
is the most studied for association with drug response. The subjects with deletion AAG 
variant experience more severe nausea and or vomiting induced by chemotherapy or 
drugs.17,18 
In our study, the frequency of the deletion AAG, and the haplotype including the deletion, 
was not significantly different between Indonesians and Caucasians. However, there 
were significant differences between the Indonesian and Caucasian population in the 
distribution of the pairs of haplotypes including the deletion AAG. Thus, differences in 
5-HT3RA antagonist response between Asians and Caucasians may be attributable to the 
differences in haplotype pairs that exist in each population. Further studies are needed to 
understand the effect of the deletion AAG or its haplotype in Asian patients in relation to 
unresponsiveness to 5-HT3RAs.
In chapter 3, we conducted a prospective cohort study which enrolled 202 chemotherapy 
naïve patients. Patients were treated with cisplatin at a dosage ≥ 50 mg/m2 as monotherapy 
or as combined chemotherapy. Ondansetron 8 mg and dexamethasone 8 mg intravenously 
were standard antiemetic therapy for prevention of acute CINV. Meanwhile, metoclo-
pramide 10 mg orally, 3 times per day as fixed prescription was given until 5 days after 
chemotherapy to prevent delayed CINV. The following SNPs were determined in ABCB1: 
rs1045642, rs2032582, rs1128503; in 5-HT3B-R: rs3831455, rs4938058, rs7943062 and in 
CYP2D6: rs16947 (CYP2D6*2), rs3892097 (CYP2D6*4), rs1065852 (CYP2D6*10) using 
Taqman assays to understand the association between gene polymorphism and antiemetic 
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drugs response. It was confirmed that ondansetron and dexamethasone could prevent about 
80% of patients from acute nausea and 70% of patients from acute vomiting. In the delayed 
phase, with metoclopramide, 60% of the patients experienced no nausea and/or vomiting. 
These percentages are lower than commonly seen with the use of the neurokinin-1 antagonist 
aprepitant during the acute phase or with the use of dexamethasone for prevention during 
the delayed phase. Earlier studies suggested that the antiemetic response is related to 
patients’ characteristics, such as younger age, female, history of alcohol drinking and 
history of emesis during pregnancy.19 However, in our study such a relationship could not be 
confirmed probably due to small sample size of male patients and no patients have history of 
alcohol drinking.
Regarding pharmacogenetic associations, this study showed that genetic variants in 
ABCB1, 5-HT3B receptor and CYP2D6 were not related to ondansetron efficacy in acute 
CINV. However, the carriership of the CTG haplotype in the ABCB1 gene increases the 
risk of delayed CINV and therefore modifies the effect of metoclopramide. The proposed 
mechanism is that passage of metoclopramide across the blood-brain barrier is increased 
in absence of an active P-gp. Indeed, metoclopramide’s site of action as an antiemetic is 
thought to be in the fourth ventricle, which is located behind the blood-blood brain barrier. 
The role of P-gp in metoclopramide transport in the central nervous system is consistent 
with the finding of and increased metoclopramide concentration in the central nervous 
system in patients with an inactive P-gp leading to extra pyramidal symptoms.7 
According to the haplotypes of 5-HT3B receptor gene, we found that the percentage of 
patients who experienced acute nausea and vomiting seemed to be higher in carriers of the 
AAGAG haplotype, although it did not reach statistical significance. Patients carrying the 
deletion AAG haplotype in 5-HT3B receptor experienced a non statistical significant of 
lower grade nausea and a higher grade vomiting in the acute phase compared to the other 
haplotypes. Since the low frequency of predicted phenotypes of UM and PM in Asian,6 we 
only found predicted phenotypes of EM and IM in our patients. Thus, the role of CYP2D6 
phenotype in explaining variability in ondansetron and metoclopramide efficacy in Asians 
seems to be limited if present at all. 
The impact of delayed CINV on patients QoL
QoL is one of the cancer patients’ outcome during their treatment. However, QoL studies 
in Indonesia are still rare. One reason is that validated instruments to assess QoL in the 
Indonesian language are absent. Therefore, we developed an Indonesian version of a 
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forward-backward translation of the EORTC QLQ-C30 into the Indonesian language was 
accomplished and in compliance with the procedures developed by the EORTC Quality 
of Life Study Group.7 The validity evaluation included convergent, discriminant, known-
groups validity, construct validity and factor analysis. The Indonesian version of SF-36 was 
used as a gold standard in the construct validity evaluation. After the pilot testing, validity 
and reliability evaluation, the Indonesian version of EORTC QLQ-C30 was concluded to be 
acceptable for assessing psychometric properties and could be used to measure Indonesian 
cancer patients’ QoL. This scale development will help clinicians to describe the human 
side of cancer treatment in Indonesia. The practicing oncologist can benefit greatly from 
the work that was performed in developing and validating this scale, by applying the 
instrument to the selection of treatment modalities based on both treatment efficacy and 
the patient’s wishes. In the future, the development of the instruments in an Indonesian 
version is required to achieve ideal tools to measure psychometric properties. We applied 
the instrument developed in chapter 6 to assess the QoL in Indonesian cancer patients 
treated with highly emetogenic chemotherapy. The hypothesis was that the occurrence 
of delayed CINV in Indonesian cancer patients would lead to significant negative impact 
on patients’ QoL. 
In chapter 6 it is confirmed that the use of suboptimal prophylactic antiemetics during 
the delayed phase of CINV decreases patients’ QoL. This study was carried out as a 
prospective non-interventional cohort design, thus all of the gynecologic cancer patients 
treated with antiemetic drugs who were appropriate to the hospital standard were 
included in the QoL study. Ondansetron and dexamethasone were administered to the 
patients one hour before cisplatin treatment. After that, metoclopramide was given to the 
patients during 4 days. Despite prophylaxis there were significant differences between the 
response and no response groups in fatigue, nausea, vomiting, and appetite loss. The “no 
response” patients experienced more severe symptoms than “response” patients in whom 
the attempted prevention of nausea and vomiting was effective, according to the diary 
data. We also considered patients’ characteristic which could interfere with patients’ QoL 
after chemotherapy, but we did not find the significant influence of the characteristics. 
We conclude that delayed emesis should be closely monitored which could improve the 
patients’ QoL in addition to the patients’ adherence in the next cycles of chemotherapy. 
Cognitive-behavioral interventions, counseling and supportive therapy seem to be 
additional promising strategies to improve gynecological cancer patients’ QoL and their 
survivorship.22,23
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Perspectives
Improvement of control of both acute and delayed CINV in cancer patients in Indonesia 
is needed to get maximal benefit from chemotherapy. Therefore, the optimal antiemetic 
drugs to prevent delayed CINV should be recommended and applied according to 
the international standard. However, some financial difficulties related to the cost of 
antiemetics should be considered by the physician in Indonesia with prescribing another 
antiemetic. The physician may prescribe other antiemetics which have similar efficacy as 
the internationally recommended antiemetic regimen or increase the dose of standard 
antiemetics.  
According to this situation, besides ondansetron, the other 5-HT3RAs can be used in 
combination with dexamethasone to reach optimal antiemetic treatment. The different 
pharmacokinetic profiles of the other 5-HT3RAs such as tropisetron, palonosetron, 
dolasetron and granisetron can modify the antiemetic response. Palonosetron which has the 
longest elimination half-life among the 5-HTRAs can be considered in preventing delayed 
nausea vomiting.24 Alternatively, other antiemetics to prevent the delayed emesis could 
be considered, besides metoclopramide. Gabapentin and olanzapine may be alternative 
antiemetics to prevent acute and delayed CINV in Indonesia health perspective. These 
two drugs are available in Indonesia at affordable costs.25,26
The benefits of chemotherapy in cancer care are usually depicted in terms of response rate, 
progression free survival, overall survival, and remission rate. Increasingly, QoL from the 
patient’s perspective is considered as a clinical endpoint of treatment. Valid instruments 
in different languages are needed to assess the cancer patients’ daily function across the 
world, both in developed and developing countries. An Indonesian version of EORTC 
QLQ-C30 is now available and this questionnaire is suitable for all types of cancer. For 
the future, development of cancer type specific questionnaires such as for cervical cancer 
in Indonesian language is warranted.
As shown delayed CINV has significant impact on the patients’ QoL. Therefore, supportive 
care by healthcare providers before, during and after chemotherapy should be improved 
and benefit the patient. This supportive treatment needs broad collaboration among 
the oncologist, psychologist, nurse, pharmacist and the patient’s family. Specifically for 
Indonesia, the close social relationship between the cancer patient, family and neighborhood 
in Indonesia offers an opportunity to increase some of the patients’ functions, despite the 
limited health facilities.
Since we found no significant associations between patients’ characteristics or genetic 
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in acute and delayed CINV (> 20%) is still unclear. Only involvement of the carriership 
of CTG in the ABCB1 gene could explain suboptimal effects of antiemetic response to 
metoclopramide in the delayed phase. Functional studies, for example pharmacokinetics 
of metoclopramide, to confirm this relationship need to be performed.  
Interestingly, there are major differences in interethnic response to drugs. Differences 
in genetic variations among races may explain the variability of antiemetics’ response 
in oncology.8 To some extent interethnic differences in drug response can be predicted 
form differences in allele frequencies among races. For example, for CYP2D6 phenotype 
it is known that the frequency of PMs in Asians is 2.0-4.8%, while in Caucasian it is 5.0-
10.0%.27 Therefore, it can be predicted that the impact of CYP2D6 genetic variants on 
drug response of CYP2D6 substrates is lower in Asians as compared to in Caucasians. 
Indeed, we did not find an association between CYP2D6 phenotypes and ondansetron and 
metoclopramide efficacy. An alternative explanation is that ondansetron is also metabolized 
by CYP3A4 and polymorphisms in the genes encoding CYP3A4/5 may have a role in the 
pharmacokinetic of ondansetron.
In addition, drugs like ondansetron have a complex pharmacology and therefore studies 
on the variation in the genes encoding 5-HT3B receptor may not fully account for 
variability in the pharmacodynamics. Since ondansetron also binds to the 5-HT1A, C, D, 
α-adrenergic, and μ-opioid receptors, future pharmacogenetic studies should also include 
genetic variants in these receptors.
In this thesis, we presented that the unsatisfactory antiemetic drugs effect in acute and 
delayed phase may cause the deterioration of QoL. In order to explore the causal factors 
of the unsatisfactory drug response, pharmacogenetics related to genes encoding enzymes 
and transporters which have significant role on disposition and metabolism of ondansetron 
and metoclopramide was investigated. Further studies would include pharmacokinetics 
of ondansetron and metoclopramide.
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Cancer is the fourth leading cause of death in Indonesia in 2005 and it is estimated to 
become the third in 2030. Chemotherapy, one of the cancer treatment choices, can increase 
the progression-free survival and overall survival time. However, patients who are treated 
with cytotoxic agents are also experiencing side effects and they may refuse to continue 
the next cycles of chemotherapy. 
Nausea and vomiting are well known side effects related to chemotherapy. Indeed, nausea 
and vomiting are the most distressing side effects of chemotherapy in cancer patients. 
Dopamine, serotonin and neurokinin1 are thought to be the neurotransmitters that play 
role in the pathophysiology of Chemotherapy Induced Nausea Vomiting (CINV). Thus, the 
antagonists of those neurotransmitters are considered as prophylactic antiemetics for CINV. 
In the 1990s, the use of 5-hydroxytriptamine 3 receptor antagonists (5-HT3RAs) highly 
improved the patients’ response rate to antiemetic drugs. In addition, the combination of a 
neurokinin 1 antagonist, a 5HT3RA and a corticosteroid can further increase the response 
rate up by 15% in acute phase and 20% in delayed phase. Thus, the international guideline 
of clinical oncology recommend this combination as prophylactic antiemetic drugs in 
the acute phase and a combination of dexamethasone – metoclopramide as prophylactic 
antiemetics in the delayed phase.
However, when the standard antiemetic drug regimens are administered to patients, 
there are still 20-30% patients in the acute phase and 40% patients in the delayed phase 
experiencing CINV. Thus, there is a high interindividual variability in response to 
antiemetic drugs in oncology patients. Some patient characteristics such as female gender, 
younger patients and history of alcohol drinking could increase the risk of CINV from 
20% to 70%. Therefore, individualizing of the use of antiemetics could start by considering 
the patient characteristics. This thesis focuses on optimizing the prevention and treatment 
of CINV by exploration of pharmacogenetic biomarkers and determining the impact of 
CINV on QoL in Indonesian cancer patients. 
The fundamentals and clinical pharmacology including the pharmacogenetics of 
antiemetic drugs applied in oncology are described in chapter 2. This chapter clarifies the 
mechanisms of action of antiemetic drugs in preventing acute and delayed CINV based 
on the neurotransmitters which play a role in CINV. The pharmacogenetic studies on 
5-HT3RAs related to the ABCB1 gene, 5-HT3 receptors genes and CYP2D6 in Caucasian 
cancer patients are presented. 
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Pharmacogenetic study of ondansetron and metoclopramide
In chapter 4, we found that Indonesian cancer patients had significantly different 
AAGAG and AAGGG haplotype frequencies of the gene encoding the 5-HT3B receptor 
compared to healthy Caucasians. Moreover, there were significant differences between 
the Indonesian and Caucasian population in the distribution of the pairs of haplotypes 
including the deletion AAG. Therefore, the possible differences in 5-HT3RAs response 
between Asians and Caucasians may not be ascribed to differences in the frequency of 
the deletion AAG but may be due to the differences in haplotype pairs that exist in the 
populations. This finding could be useful for understanding interethnic differences 
in drug response of drugs targeting the 5-HT3B receptor in cancer treatment related 
emesis. 
A clinical pharmacogenetic study investigating the association of variants in the genes 
encoding ABCB1, the 5-HT3B receptor and CYP2D6 with CINV in Indonesian cancer 
patients is presented in chapter 3. This study shows that there is no association of variants 
between genes encoding ABCB1, the 5-HT3B receptor or CYP2D6 and ondansetron 
response. However, the carriership of the CTG haplotype in the ABCB1 gene increases 
the risk of delayed CINV and may therefore modify the effect of metoclopramide in the 
delayed phase. The proposed mechanism is that passage of metoclopramide across the 
blood-brain barrier is increased in absence of an active P-gp. Indeed, metoclopramide’s 
site of action as an antiemetic is thought to be in the fourth ventricle, which is located 
behind the blood-blood brain barrier. The role of P-gp in metoclopramide transport in 
the central nervous system is consistent with the finding of and increased metoclopramide 
concentration in the central nervous system in patients with an inactive P-gp leading to 
extra pyramidal symptoms.
Impact of CINV to the patients‘ quality of life
Chapter 5 of this thesis provides the results of a study on the translation and validation of 
the EORTC QLQ-C30 in the Indonesian language. The forward-backward translation of 
EORTC QLQ-C30 into the Indonesian language was in compliance with the procedures 
developed by the EORTC Quality of Life Study Group. The validity evaluation included 
convergent, discriminant, known-groups validity, construct validity and factor analysis. The 
Indonesian version of SF-36 was used as gold standard in the construct validity evaluation. 
After the pilot testing, validity and reliability evaluation, the Indonesian version of EORTC 
QLQ-C30 was suggested to have acceptable psychometric properties and could be used 






Chapter 6 reports that the use of suboptimal prophylactic antiemetics during the delayed 
phase of CINV decreases patients’ quality of life. The augmentation of dexamethasone 
during the delayed phase could increase the metoclopramide efficacy. This study was carried 
out by prospective non-interventional cohort design, thus all of the gynecologic cancer 
patients were treated by antiemetic drugs which were according to the hospital standard. 
The ondansetron and dexamethason were administered to the patients one hour before 
cisplatin treatment. After that, metoclopramide was given to the patients over 4 days.
The final chapter of this thesis is the discussion of the result and the future directions. 
Further study is needed to investigate the association between pharmacokinetic profiles 
of metoclopramide and its efficacy during the delayed phase to confirm the modification 
effect of metoclopramide due to the carriership of CTG haplotypes of ABCB1 gene. The 
pharmacogenetic studies of ondansetron can be expanded in the future by including 
variants encoding other relevant genes such as the CYP3A4, 5-HT1B, 5-HT1C, α-adrenergic, 
μ-opioid, 5-HT3A, B, C, D and E. 
Meanwhile, using combination of the other 5-HT3RAs besides ondansetron, and 
dexamethasone to get the optimal treatment of antiemetic during the acute phase should be 
considered. Otherwise, the augmentation of dexamethasone during the delayed phase may 
increase the metoclopramid efficacy. Gabapentin and olanzapine may be the alternatives 
of antiemetics to prevent acute and delayed CINV in Indonesia health perspective.  
In the future, the incidence of cervical cancer will increase in Indonesia, and therefore 
further studies aimed at translation and validation of EORTC QLQ for specific types of 
cancer such as cervical cancer is called.
The high impact of CINV on patients’ quality of life warrants adequate supportive care 
from the healthcare providers before, during and after chemotherapy is applied. This 
supportive treatment needs close collaboration between the oncologist, psychologist, 
nurse, pharmacist and the family. The close social relationship among the cancer patient, 
the family and neighborhood in Indonesia could increase some of the patients’ functions, 






Kanker merupakan penyebab kematian peringkat keempat di Indonesia pada tahun 
2005 dan diperkirakan akan menjadi penyebab kematian peringkat ketiga pada tahun 
2030. Kemoterapi masih merupakan salah satu pilihan terapi untuk kanker dan dapat 
meningkatkan progression-free survival (PFS) dan overall survival time (OS) pasien kanker. 
Namun pasien yang mendapat terapi dengan bahan sitotoksik tersebut juga akan mengalami 
efek samping obat. Akibat mengalami efek samping obat, pasien mungkin akan menolak 
untuk melanjutkan kemoterapi siklus selanjutnya. 
Mual dan muntah merupakan salah satu efek samping kemoterapi yang paling dikenal dan 
paling dicemaskan oleh pasien. Dopamin, serotonin (hidroksitriptamin) dan neurokinin-1 
merupakan neurotransmiter yang berperan dalam patofisiologi mual muntah pada pemberian 
kemoterapi. Oleh karena itu obat yang bekerja sebagai penghambat reseptor dopamine, 
serotonin dan neurokinin-1 merupakan antiemetik profilaksi mual muntah pada pemberian 
kemoterapi. Sejak 1990, antagonis reseptor 5-hidroksitriptamin 3 (5-HT3) digunakan untuk 
meningkatkan respon pasien terhadap terapi antiemetik konvensional. Kombinasi antagonis 
neurokinin-1, antagonis reseptor 5-HT3 dan deksametason menunjukkan peningkatan 
respon pasien sebesar 15% pada fase akut dan 20% pada fase tertunda. Oleh karena itu 
Perhimpunan Ahli Onkologi Klinis Internasional merekomendasikan kombinasi pengobatan 
tersebut pada fase akut dan kombinasi metoklopramid -deksametason pada fase tertunda. 
Meskipun pasien kanker sudah mendapat terapi antiemetik profilaksi yang sesuai dengan 
standar, namun 20-30% penderita pada fase akut dan 40% pasien pada fase tertunda masih 
mengalami mual muntah akibat kemoterapi. Efek yang tidak optimal ini dapat disebabkan 
karena variasi individu. Faktor karakteristik pasien seperti wanita, usia muda dan riwayat 
konsumsi alkohol meningkatkan risiko terjadinya mual muntah akibat pemberian 
kemoterapi dari 20% menjadi 70%. Sehingga pemberian antiemetik pada fase akut dan 
tertunda sebaiknya mempertimbangkan variasi individu dan karakteristik pasien.
Tujuan penyusunan tesis ini adalah untuk optimalisasi terapi dan pencegahan mual 
muntah pada pemberian kemoterapi dengan mempertimbangkan aspek farmakogenetik 
dari biomarker dan mengetahui pengaruh mual muntah pada pemberian kemoterapi 
terhadap kualitas hidup pasien kanker. 
Bab II dari tesis ini berisi tentang review farmakologi fundamental, klinik, dan genetik dari 
antiemetik dibidang onkologi. Di dalam bab ini dijelaskan mekanisme aksi dari obat-obat 
antiemetik dalam mengatasi mual muntah akibat kemoterapi baik pada fase akut maupun 
fase tertunda. Adanya hubungan antara variasi gen ABCB1 (ATP-Binding Casette Sub-family 




Penelitian farmakogenetik ondansetron dan metoklopramid
Di dalam Bab IV, ditemukan adanya perbedaan frekuensi haplotipe AAGAA dan 
AAGGG yang signifikan pada ras Asia dan Kaukasia. Selanjutnya, ditemukan juga 
adanya perbedaan distribusi pasangan haplotipe deletion AAG antara kedua ras tersebut. 
Hal ini memungkinkan timbulnya perbedaan respon antiemetik antara ras Asia dan 
Kaukasia. Penelitian ini juga menjelaskan adanya perbedaan respon berdasarkan aspek 
farmakodimanika reseptor 5-HT3B pada kedua ras tersebut.   
Hubungan antara variasi gen yang mengkoding ABCB1, reseptor 5-HT3B dan CYP2D6 
dengan mual muntah akibat kemoterapi pada pasien kanker di Indonesia dijelaskan di Bab 
III. Hasil penelitian ini menemukan bahwa tidak ada hubungan antara variasi gen yang 
mengkoding ABCB1, reseptor 5-HT3B dan CYP2D6 dan respon ondansetron. Namun, 
pembawa haplotipe CTG dari gen ABCB1 dapat meningkatkan risiko mual muntah akibat 
kemoterapi pada fase tertunda dan akan memodifikasi efek dari metoklopramid pada fase 
tersebut. Metoklopramid dapat melalui sawar otak dengan adanya inaktivasi P-glikoprotein 
(P-gp). Sedangkan tempat aksi metoklopramid adalah di ventrikel keempat yang terletak di 
luar sawar otak. Dengan adanya P-gp yang inaktif maka lebih banyak metoklopramid yang 
mampu melalui sawar otak sehingga menimbulkan efek samping sindroma ekstrapiramidal. 
Namun hanya sedikit metoklopramid yang tersedia di ventrikel ke empat, sehingga efikasi 
metoklopramid berkurang.
Pengaruh mual muntah akibat kemoterapi terhadap kualitas hidup pasien
Bab V tesis ini menjelaskan tentang proses translasi dan validasi kuesioner EORTC 
QLQ-C30 ke dalam versi bahasa Indonesia. Proses translasi forward-backward kuesioner ini 
ke dalam bahasa Indonesia mengikuti prosedur yang sudah ditentukan oleh EORTC Quality 
of Life Study Group. Prosedur validasi meliputi validasi konvergen, validasi diskriminan, 
validasi kelompok, analisis faktor dan validasi konstrak. Kuesioner SF-36 versi Indonesia 
digunakan sebagai acuan dalam validasi konstrak. Setelah dilakukan uji pendahuluan 
dan uji validitas, maka kuesioner EORTC QLQ-30 dapat digunakan sebagai instrument 
pengukur kualitas hidup pada pasien kanker di Indonesia. 
Bab VI menjelaskan kualitas hidup pasien setelah pemberian kemoterapi. Pada studi ini 
ditemukan adanya pemberian antiemetik suboptimal pada fase tertunda yang menimbulkan 
mual muntah pada pemberian kemoterapi sehingga mengurangi kualitas hidup pasien. 
Untuk itu disarankan penambahan deksametason pada fase ini untuk meningkatkan efikasi 
metoklopramid. Rancangan penelitian ini adalah kohort prospektif non intervensional, 





tertunda sesuai dengan standar yang sudah ditentukan di rumah sakit. Antiemetik yang 
diberikan pada pasien adalah ondansetron 8 mg iv dan deksametason 8 mg iv satu jam 
sebelum terapi cisplatin dan metoklopramid 10 mg oral pada hari kedua sampai kelima 
setelah kemotgerapi. 
Dalam bab terakhir tesis ini, peneliti berharap adanya penelitian lanjutan untuk 
mengetahui hubungan profil farmakokinetik dari metoklopramid dan efikasinya pada fase 
tertunda. Hal ini ditujukan untuk mengkonfirmasi efek modifikasi haplotipe CTG pada 
gen ABCB1 terhadap metoklopramid. Selanjutnya studi farmakogenetik ondansetron dapat 
dilakukan pada gen yang mengkode CYP3A4, 5-HT1B, 5-HT1C, α-adrenergic, μ-opioid, 
5-HT3A, B, C, D dan E. 
Pemberian antiemetik golongan antagonis reseptor 5-HT3 pada fase akut, selain kombinasi 
ondansetron-deksametason perlu dipertimbangkan juga jenis yang lain. Penambahan 
gabapentin atau olanzapine pada kombinasi ondansteron-deksametason dapat digunakan 
sebagai alternatif antiemetik pada fase akut dan tertunda di Indonesia. 
Insidensi penyakit kanker di Indonesia semakin meningkat. Sehingga studi lebih lanjut 
mengenai translasi dan validasi EORTC QLQ-C30 yang sesuai dengan tipe kanker yang 
spesifik sangat diperlukan di Indonesia. 
Adanya penurunan kualitas hidup yang cukup signifikan akibat efek mual muntah pada 
pemberian kemoterapi menunjukkan pentingnya peningkatan pelayanan penunjang di 
penyedia sarana kesehatan baik sebelum, selama atau sesudah kemoterapi di Indonesia. 
Pelayanan penunjang ini memerlukan kerjasama dari ahli onkologi, ahli psikologi, perawat, 
apoteker dan juga dari keluarga pasien sendiri. Adanya hubungan sosial yang sangat dekat 
antara pasien, keluarga pasien dan lingkungan sosial dapat meningkatkan kualitas hidup 






Kanker was de vierde doodsoorzaak in Indonesië in 2005 en naar verwachting wordt kanker 
de derde doodsoorzaak in 2030. Chemotherapie, één van de behandelingsmogelijkheden 
van kanker, kan de progressie-vrije overleving en de algehele duur van overleving 
vergroten. Echter, de patiënten die worden behandeld met chemotherapie ondervinden 
veel bijwerkingen die kunnen resulteren in het staken van de therapie. 
Misselijkheid en braken zijn bekende bijwerkingen van chemotherapie en worden als zeer 
belastende bijwerkingen ervaren door patiënten met kanker. Verondersteld wordt dat de 
neurotransmitters dopamine, serotonine en neurokinine 1 een cruciale rol spelen bij het 
ontstaan van door chemotherapie geïnduceerde misselijkheid en braken (Chemotherapy 
Induced Nausea and Vomiting, hierna: CINV). 
Antagonisten van deze neurotransmitters worden met succes toegepast als profylactische 
anti-emetica voor CINV. In de jaren negentig werd de behandeling van CINV met 
de introductie van 5-hydroxytriptamine receptor antagonisten (5-HT3RAs) sterk 
verbeterd. Door combinatie van een 5HT3RA en een corticosteroïd werd de responskans 
verder verhoogd met 15% in de acute fase en 20% in de late fase. Daarom adviseert de 
internationale richtlijn voor klinische oncologie deze combinatie als profylactische anti-
emetische geneesmiddelen in de acute fase en een combinatie van dexamethason en 
metoclopramide als profylactisch beleid in de late fase.
Echter, als dit standaard anti-emetisch regime wordt toegepast bij patiënten, blijkt 
nog steeds 20 tot 30% van de patiënten in de acute fase en 40% in de late fase last van 
CNIV te ondervinden. Dit betekent dat er onder de behandelde patiënten met kanker 
een grote interindividuele variabiliteit in respons op anti-emetica bestaat. Sommige 
patiëntkarakteristieken, zoals het vrouwelijke geslacht, jonge leeftijd en alcoholgebruik, 
kunnen de kans op CINV verhogen van 20 naar 70%. Dit geeft aan dat patiëntkarakteristieken 
een rol kunnen spelen bij het individueel afstemmen van de anti-emetische therapie. Dit 
proefschrift richt zich op het bepalen van de gevolgen van CINV op de kwaliteit van leven 
(hierna: QoL) in Indonesische patiënten met kanker en op het verder optimaliseren van de 
behandeling en voorkomen van CINV door toepassing van farmacogenetische biomarkers. 
De basisprincipes en klinische farmacologie inclusief de farmacogenetica van de anti-
emetica gebruikt in de oncologie worden beschreven in hoofdstuk 2. Dit hoofdstuk 
beschrijft de werkingsmechanismen van de anti-emetica bij het voorkomen van acute 
en vertraagde CINV in relatie tot de neurotransmitters die een rol spelen bij CINV. De 
farmacogenetische onderzoeken naar 5HT3RA’s in relatie tot ABCB1, 5-HT3 receptoren 
en CYP2D6 in Kaukasische patiënten met kanker worden gepresenteerd. 
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Farmacogenetisch onderzoek van ondansetron en metoclopramide
In hoofdstuk 4 laten wij zien dat Indonesische patiënten met kanker significant andere 
frequenties hebben van het AAGAG en AAGGG haplotype van het gen dat codeert 
voor de 5-HT3B receptor in vergelijking met gezonde Kaukasiërs. Bovendien waren er 
significante verschillen tussen de Indonesische en Kaukasische populatie in de verdeling 
van de haplotypen, waaronder de depletie van AAG. Daarom kan het mogelijke verschil 
in respons in 5-HT3RA tussen Aziaten en Kaukasiërs niet worden toegeschreven aan 
de verschillen van de AAG-depletie, maar wellicht wel aan het verschil in haplotypen 
tussen beide etniciteiten. Deze belangrijke bevinding kan de interetnische verschillen 
in respons van op 5-HT3B receptor antagonisten bij patiënten met kanker mogelijk 
verklaren.
Een klinisch farmacogenetisch onderzoek naar de associatie tussen variaties in 
de genen die coderen voor ABCB1, de 5-HT3B receptoren en CYP2D6 en CINV 
in Indonesische patiënten met kanker wordt gepresenteerd in hoofdstuk 3. Dit 
onderzoek laat zien dat er geen associatie is tussen de variaties in deze genen en de 
respons op ondansetron. Echter, dragerschap van het CTG haplotype in het ABCB1 
gen, dat codeert voor het transportereiwit P-gp, verhoogt de kans op vertraagd CINV 
en zou daarmee het effect van metoclopramide in deze fase kunnen beïnvloeden. 
Het veronderstelde werkingsmechanisme is dat passage van metoclopramide over de 
bloed-hersenbarrière is toegenomen bij afwezigheid van actief P-gp. Immers, de plaats 
van werking van metoclopramide is gelegen in de vierde ventrikel, die zich achter de 
bloed-hersenbarrière bevindt. De rol van P-gp in het transport van metoclopramide 
naar het centrale zenuwstelsel stemt ook overeen met het gegeven dat er een verhoogde 
metoclopramideconcentratie in het centrale zenuwstelsel wordt gevonden in patiënten 
met een inactief P-gp dat leidt tot extrapyramidale bijwerkingen.
De invloed van CINV op de kwaliteit van leven
In hoofdstuk 5 van dit proefschrift worden de resultaten getoond van het onderzoek 
naar de vertaling en validatie van de EORTC QLQ-C30 in de Indonesische taal. De 
“forward-backward” vertaling van de EORTC QLQ-C30 in de Indonesische taal voldeed 
aan de procedures zoals ontwikkeld door de EORTC Quality of Life Study Group. De 
evaluatie van de validiteit betrof vooral constructvaliditeit. De Indonesische versie van 
de SF-36 is als gouden standaard gebruikt in het onderzoek van de psychometrische 
kenmerken van het vertaalde instrument. In het pilotonderzoek, en bij de validatie- 





acceptabele psychometrische eigenschappen zien en werd geconcludeerd dat deze 
geschikt is om de kwaliteit van leven van Indonesische patiënten met kanker vast te 
stellen.
Hoofdstuk 6 laat zien dat het gebruik van een suboptimaal profylactische anti-emeticum 
regime tijdens de vertraagde fase van CINV de kwaliteit van leven van de patiënt 
negatief beïnvloedt. Door toevoeging van dexamethason tijdens de vertraagde fase zou 
de metoclopramide effectiviteit kunnen verbeteren. Dit onderzoek werd uitgevoerd 
als een prospectief niet interveniërend cohortonderzoek, waarbij alle patiënten met 
gynaecologische kanker volgens de vigerende lokale ziekenhuisstandaard met anti-emetica 
werden behandeld. Ondansetron en dexamethason werden één uur voor de toediening 
van cisplatine aan deze patiënten toegediend. Daarna werd metoclopramide gegeven 
gedurende vier dagen. 
In dit laatste hoofdstuk worden de resultaten van dit proefschrift bediscussieerd en worden 
toekomstige onderzoeken voorgesteld.  
In de toekomst is aanvullend onderzoek nodig om de de associatie tussen de 
farmacokinetiek van metoclopramide en de effectiviteit van dit middel tijdens de 
vertraagde fase van CINV te bestuderen en om de gevonden relatie met het dragerschap 
van het CTG-haplotype van het ANCB1 gen te kunnen verklaren. Het farmacogenetisch 
onderzoek met ondansetron zou in de toekomst uitgebreid kunnen worden met andere 
potentieel relevante genen zoals CYP3A4, 5-HT1B, 5-HT1C, α-adrenerge, μ-opioide, 
5-HT3A, B, C, D en E.
Toepassing van de combinatie van andere 5-HT3RA’s dan ondansetron, met dexamethason, 
met als doel om een optimale anti-emetische behandeling gedurende de acute fase te 
bereiken, zou kunnen worden overwogen. Ook zou de toevoeging van dexamethason 
tijdens de vertraagde fase de effectiviteit van metoclopramide kunnen verhogen. 
Gabapentine en olanzapine zouden alternatieve anti-emetica kunnen zijn bij de profylaxe 
van acuut en vertraagd CINV vanuit het perspectief van de Indonesische gezondheidszorg. 
In de toekomst zal de incidentie van baarmoederhalskanker in Indonesië toenemen en om 
die reden zouden meer onderzoeken gedaan moeten worden naar de vertaling en validatie 
van ziektespecifieke versies van de EORTC QLQ C30, zoals baarmoederhalskanker.
De grote gevolgen die CINV heeft op de kwaliteit van leven van de patiënt vereisen een 
adequate ondersteunende therapie vóór, tijdens en na de behandeling met chemotherapie. 
Deze ondersteunende behandeling vereist een nauwe samenwerking tussen oncoloog, 
psycholoog, verpleegkundige, apotheker en familie. 
Samenvatting Chapter 10
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De nauwe sociale netwerken van de patiënten met kanker, de familie en directe omgeving 
in Indonesië zouden kunnen bijdragen aan het verbeteren van het welbevinden van de 
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